<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0108233947
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Dezeroga
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DAPAGLIFLOZIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        87.10
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Med city" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Med city
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Med City Pharma
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10BK01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Dezeroga</strong><strong><sup>&reg;</sup></strong> <strong>is </strong></p><p><strong>Dezeroga</strong><strong><sup>&reg;</sup></strong> contains the active substance dapagliflozin. It belongs to a group of medicines called &ldquo;sodium glucose co-transporter-2 (SGLT2) inhibitors&rdquo;. They work by blocking the SGLT2 protein in your kidney. By blocking this protein, blood sugar (glucose), salt (sodium) and water are removed from your body via the urine.</p><p><strong>&nbsp;</strong></p><p><strong>What Dezeroga</strong><strong><sup>&reg;</sup></strong> <strong>is used for </strong></p><p><strong>Dezeroga</strong><strong><sup>&reg;</sup></strong> <strong>is used in adult patients (aged 18 years and older) to treat: </strong></p><p><strong>Type 2 diabetes:</strong></p><p>If your type 2 diabetes cannot be controlled with diet and exercise.</p><p><strong>Dezeroga</strong><strong><sup>&reg;</sup></strong> can be used on its own or together with other medicines to treat diabetes.</p><p>It is important to continue to follow the advice on diet and exercise given to you by your doctor, pharmacist or nurse.</p><p>&nbsp;</p><p><strong>What is type 2 diabetes and how does Dezeroga</strong><strong><sup>&reg;</sup></strong> <strong>help? </strong></p><p>In type 2 diabetes your body does not make enough insulin or is not able to use the insulin it makes properly. This leads to a high level of sugar in your blood. This can lead to serious problems like heart or kidney disease, blindness, and poor circulation in your arms and legs.</p><p><strong>Dezeroga</strong><strong><sup>&reg; </sup></strong>works by removing excess sugar from your body. It can also help prevent heart disease.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Dezeroga</strong><strong><sup>&reg;</sup></strong><strong>:</strong></p><p>If you are allergic to dapagliflozin or any of the other ingredients of this medicine.</p><p><strong>Warnings and precautions </strong></p><p><strong>Contact a doctor or the nearest hospital straight away: </strong></p><p><strong>Diabetic ketoacidosis: </strong></p><p>If you have diabetes and experience feeling sick or being sick, stomach pain, excessive thirst, fast and deep breathing, confusion, unusual sleepiness or tiredness, a sweet smell to your breath, a sweet or metallic taste in your mouth, or a different odour to your urine or sweat or rapid weight loss.</p><p>The above symptoms could be a sign of &ldquo;diabetic ketoacidosis&rdquo; &ndash; a serious, sometimes life-threatening problem you can get with diabetes because of increased levels of &ldquo;ketone bodies&rdquo; in your urine or blood, seen in tests.</p><p>The risk of developing diabetic ketoacidosis may be increased with prolonged fasting, excessive alcohol consumption, dehydration, sudden reductions in insulin dose, or a higher need of insulin due to major surgery or serious illness.</p><p>When you are treated with <strong>Dezeroga</strong><strong><sup>&reg;</sup></strong>, diabetic ketoacidosis can occur even if your blood sugar is normal.</p><p>If you suspect you have diabetic ketoacidosis, contact a doctor or the nearest hospital straight away and do not take this medicine.</p><p>&nbsp;</p><p><strong>Talk to your doctor, pharmacist or nurse before taking Dezeroga</strong><strong><sup>&reg;</sup></strong><strong>: </strong></p><p>If you have &ldquo;type 1 diabetes&rdquo; &ndash; the type that usually starts when you are young, and your body does not produce any insulin.</p><p>If you have diabetes and have a kidney problem &ndash; your doctor may ask you to take additional or a different medicine to control your blood sugar.</p><p>If you have a liver problem &ndash; your doctor may start you on a lower dose.</p><p>If you are on medicines to lower your blood pressure (anti-hypertensives) and have a history of low blood pressure (hypotension).</p><p>If you have very high levels of sugar in your blood which may make you dehydrated (lose too much body fluid). Possible signs of dehydration are listed in section 4. Tell your doctor before you start taking <strong>Dezeroga</strong><strong><sup>&reg;</sup></strong> if you have any of these signs.</p><p>If you have or develop nausea (feeling sick), vomiting or fever or if you are not able to eat or drink. These conditions can cause dehydration. Your doctor may ask you to stop taking <strong>Dezeroga</strong><strong><sup>&reg;</sup></strong> until you recover to prevent dehydration.</p><p>If you often get infections of the urinary tract.</p><p>If any of the above applies to you (or you are not sure), talk to your doctor, pharmacist or nurse before taking <strong>Dezeroga</strong><strong><sup>&reg;</sup></strong>.</p><p><strong>Diabetes and foot care </strong></p><p>If you have diabetes, it is important to check your feet regularly and adhere to any other advice regarding foot care given by your health care professional.</p><p><strong>Kidney function</strong></p><p>If you have diabetes, your kidneys should be checked before you start taking and whilst you are on this medicine.</p><p><strong>Urine glucose </strong></p><p>Because of how <strong>Dezeroga</strong><strong><sup>&reg;</sup></strong> works, your urine will test positive for sugar while you are on this medicine.</p><p><strong>Children and adolescents </strong></p><p><strong>Dezeroga</strong><strong><sup>&reg;</sup></strong> is not recommended for children and adolescents under 18 years of age, because it has not been studied in these patients.</p><p><strong>Other medicines and Dezeroga</strong><strong><sup>&reg;</sup></strong></p><p>Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines.</p><p><strong>Especially tell your doctor: </strong></p><p>If you are taking a medicine used to remove water from the body (diuretic).</p><p>If you have type 2 diabetes and are taking other medicines that lower the amount of sugar in your blood such as insulin or a &ldquo;sulphonylurea&rdquo; medicine. Your doctor may want to lower the dose of these other medicines, to prevent you from getting low blood sugar levels (hypoglycaemia).</p><p><strong>Pregnancy and breast-feeding </strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. You should stop taking this medicine if you become pregnant, since it is not recommended during the second and third trimesters of pregnancy. Talk to your doctor about the best way to control your blood sugar while you are pregnant.</p><p>Talk to your doctor if you would like to or are breast-feeding before taking this medicine. Do not use <strong>Dezeroga</strong><strong><sup>&reg;</sup></strong> if you are breast-feeding. It is not known if this medicine passes into human breast milk.</p><p><strong>Driving and using machines </strong></p><p><strong>Dezeroga</strong><strong><sup>&reg;</sup></strong> has no or negligible influence on the ability to drive and use machines.</p><p>Taking this medicine with other medicines called sulphonylureas or with insulin can cause too low blood sugar levels (hypoglycaemia), which may cause symptoms such as shaking, sweating and change in vision, and may affect your ability to drive and use machines.</p><p>Do not drive or use any tools or machines, if you feel dizzy while taking <strong>Dezeroga</strong><strong><sup>&reg;</sup></strong>.</p><p><strong>Dezeroga</strong><strong><sup>&reg;</sup></strong> <strong>contains lactose </strong></p><p><strong>Dezeroga</strong><strong><sup>&reg;</sup></strong> contains lactose (milk sugar). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor, pharmacist or nurse if you are not sure.</p><p><strong>How much to take </strong></p><p>The recommended dose is one 10 mg tablet each day.</p><p>Your doctor may start you on a 5 mg dose if you have a liver problem.</p><p>Your doctor will prescribe the strength that is right for you.</p><p>&nbsp;</p><p><strong>Taking this medicine </strong></p><p>Swallow the tablet whole with half a glass of water.</p><p>You can take your tablet with or without food.</p><p>You can take the tablet at any time of the day. However, try to take it at the same time each day. This will help you to remember to take it.</p><p>Your doctor may prescribe <strong>Dezeroga</strong><strong><sup>&reg;</sup></strong> together with other medicine(s). Remember to take these other medicine(s) as your doctor has told you. This will help get the best results for your health.</p><p>Diet and exercise can help your body use its blood sugar better. If you have diabetes, it is important to stay on any diet and exercise program recommended by your doctor while taking <strong>Dezeroga</strong><strong><sup>&reg;</sup></strong>.</p><p><strong>If you take more Dezeroga</strong><strong><sup>&reg;</sup></strong> <strong>than you should</strong></p><p>If you take more <strong>Dezeroga</strong><strong><sup>&reg;</sup></strong> tablets than you should, talk to a doctor or go to a hospital immediately. Take the medicine pack with you.</p><p><strong>If you forget to take Dezeroga</strong><strong><sup>&reg;</sup></strong></p><p>What to do if you forget to take a tablet depends on how long it is until your next dose.</p><p>If it is 12 hours or more until your next dose, take a dose of <strong>Dezeroga</strong><strong><sup>&reg;</sup></strong> as soon as you remember. Then take your next dose at the usual time.</p><p>If it is less than 12 hours until your next dose, skip the missed dose. Then take your next dose at the usual time.</p><p>Do not take a double dose of <strong>Dezeroga</strong><strong><sup>&reg;</sup></strong> to make up for a forgotten dose.</p><p><strong>If you stop taking Dezeroga</strong><strong><sup>&reg;</sup></strong></p><p>Do not stop taking <strong>Dezeroga</strong><strong><sup>&reg;</sup></strong> without talking to your doctor first. If you have diabetes, your blood sugar may increase without this medicine.</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Contact a doctor or the nearest hospital straight away if you have any of the following side effects: </strong></p><p>Diabetic ketoacidosis - this is rare in patients with type 2 diabetes (may affect up to 1 in 1,000 people).</p><p><strong>These are the signs of diabetic ketoacidosis: </strong></p><p>Increased levels of &ldquo;ketone bodies&rdquo; in your urine or blood.</p><p>Feeling sick or being sick.</p><p>Stomach pain.</p><p>Excessive thirst.</p><p>Fast and deep breathing.</p><p>Confusion.</p><p>Unusual sleepiness or tiredness.</p><p>A sweet smell to your breath, a sweet or metallic taste in your mouth or a different odour to your urine or sweat.</p><p>Rapid weight loss.</p><p>This may occur regardless of blood sugar level. Your doctor may decide to temporarily or permanently stop your treatment with <strong>Dezeroga</strong><strong><sup>&reg;</sup></strong>.</p><p>&nbsp;</p><p><strong>Stop taking Dezeroga</strong><strong><sup>&reg; </sup></strong><strong>and see a doctor as soon as possible if you notice any of the</strong><strong> </strong><strong>following serious side effects: </strong></p><p>Urinary tract infection, seen commonly (may affect up to 1 in 10 people).</p><p><strong>These are signs of a severe infection of the urinary tract: </strong></p><p>Fever and/or chills.</p><p>Burning sensation when passing water (urinating).</p><p>Pain in your back or side.</p><p>Although uncommon, if you see blood in your urine, tell your doctor immediately.</p><p><strong>Contact your doctor as soon as possible if you have any of the following side effects: </strong></p><p>Low blood sugar levels (hypoglycaemia), seen very commonly (may affect more than 1 in 10 people) in patients with diabetes taking this medicine with a sulphonylurea or insulin.</p><p><strong>These are the signs of low blood sugar: </strong></p><p>Shaking, sweating, feeling very anxious, fast heartbeat.</p><p>Feeling hungry, headache, change in vision.</p><p>A change in your mood or feeling confused.</p><p>Your doctor will tell you how to treat low blood sugar levels and what to do if you get any of the signs above.</p><p><strong>&nbsp;</strong></p><p><strong>Other side effects when taking dapagliflozin: </strong></p><p><strong>Common </strong></p><p>Genital infection (thrush) of your penis or vagina (signs may include irritation, itching, unusual discharge or odour).</p><p>Back pain.</p><p>Passing more water (urine) than usual or needing to pass water more often.</p><p>Changes in the amount of cholesterol or fats in your blood (shown in tests).</p><p>Increases in the amount of red blood cells in your blood (shown in tests).</p><p>Decreases in creatinine renal clearance (shown in tests) in the beginning of treatment.</p><p>Dizziness.</p><p>Rash.</p><p><strong>Uncommon (may affect up to 1 in 100 people):</strong></p><p>Loss of too much fluid from your body (dehydration, signs may include very dry or sticky mouth, passing little or no urine or fast heartbeat).</p><p>Thirst.</p><p>Constipation.</p><p>Awakening from sleep at night to pass urine.</p><p>Dry mouth.</p><p>Weight decreased.</p><p>Increases in creatinine (shown in laboratory blood tests) in the beginning of treatment.</p><p>Increases in urea (shown in laboratory blood tests).</p><p><strong>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. </strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>Do not use <strong>Dezeroga</strong><strong><sup>&reg;</sup></strong><strong> </strong>tablets after the expiry date (EXP) which is stated on the blister and the carton.</p><p>The expiry date refers to the last day of that month.</p><p><strong>Dezeroga</strong><strong><sup>&reg;</sup></strong><strong> </strong>tablets: Store below 30&deg;C.</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Dezeroga</strong><strong><sup>&reg;</sup></strong><strong> tablets contain</strong></p><p>The active substance is dapagliflozin.</p><p>The other ingredients are Lactose Anhydrous, microcrystalline cellulose, crospovidone, colloidal anhydrous silica, magnesium stearate, Opadry II Yellow Powder (Polyvinyl alcohol, titanium dioxide, Macrogol/ PEG, talc, yellow iron oxide).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Dezeroga® 10 mg: Yellow diamond biconvex beveled edge film coated tablet engraved with C37 on one face and plain on the other face, presented in Alu/Alu blisters, intended for oral use.
Pack size: 28 Film Coated Tablets.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Med City Pharma-KSA.</strong></p><p>1st Industrial city, Phase 5, Jeddah &ndash;KSA.</p><p>Tel: 00966920003288</p><p>Mobile: 00966555786968</p><p>P.O .Box: 4072 - Jeddah 22429</p><p>E-mail: info@medcitypharma.com</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                07/2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو </strong><strong>ديزيروجا</strong><strong><sup>&reg;</sup></strong></p><p dir="RTL">يحتوي <strong>ديزيروجا</strong><strong><sup>&reg;</sup></strong> على المادة الفعالة داباجليفلوزين. والتي تنتمي إلى مجموعة من الأدوية تعرف بمثبطات الناقل المشترك-2 للصوديوم والجلوكوز. والتي تعمل عن طريق حصر البروتين المثبط للناقل المشترك-2 للصوديوم والجلوكوز في الكلى. وينتج عن حصر هذا البروتين إخراج سكر الدم (الجلوكوز)، الملح (الصوديوم) والماء من الجسم عن طريق البول.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما هي دواعي استعمال </strong><strong>ديزيروجا</strong><strong><sup>&reg;</sup></strong></p><p dir="RTL"><strong>يستعمل</strong><strong> </strong><strong>ديزيروجا</strong><strong><sup>&reg; </sup></strong><strong>للمرضى</strong><strong> </strong><strong>البالغين</strong><strong> (</strong><strong>الذين</strong><strong> </strong><strong>تبلغ</strong><strong> </strong><strong>أعمارهم</strong><strong> 18 </strong><strong>عاما</strong><strong> </strong><strong>وأكبر</strong><strong>) </strong><strong>لعلاج</strong><strong> </strong><strong>الحالات</strong><strong> </strong><strong>التالية</strong><strong>:</strong></p><p dir="RTL"><strong>النوع</strong><strong> </strong><strong>الثاني</strong><strong> </strong><strong>من</strong><strong> </strong><strong>داء</strong><strong> </strong><strong>السكري</strong><strong>:</strong></p><p dir="RTL">إذا لم يتم السيطرة لديك على داء السكري من النوع الثاني باتباع نظام غذائي أو ممارسة التمرينات الرياضية.</p><p dir="RTL">من الممكن استعمال <strong>ديزيروجا</strong><strong><sup>&reg; </sup></strong>لوحده أو مع أدوية أخرى لعلاج داء السكري.</p><p dir="RTL">من الضروري الاستمرار باتباع النصائح المقدمة لك من قبل الطبيب، الصيدلي أو الممرض والمتعلقة بالنظام الغذائي وممارسة التمرينات الرياضية.</p><p dir="RTL"><strong>ما</strong><strong> </strong><strong>هو</strong><strong> </strong><strong>النوع</strong><strong> </strong><strong>الثاني</strong><strong> </strong><strong>من</strong><strong> </strong><strong>داء</strong><strong> </strong><strong>السكري</strong><strong> </strong><strong>وكيف</strong><strong> </strong><strong>يساعد</strong><strong> </strong><strong>ديزيروجا</strong><strong><sup>&reg; </sup></strong><strong>في</strong><strong> </strong><strong>هذه</strong><strong> </strong><strong>الحالة؟</strong></p><p dir="RTL">في النوع الثاني من داء السكري لا يستطيع الجسم إنتاج كمية كافية من الإنسولين أو أنه لا يستطيع استعمال الإنسولين الذي ينتجه بطريقة صحيحة. وهذا يؤدي إلى ارتفاع مستوى السكر في الدم. وهذا قد يؤدي إلى حدوث مشاكل خطيرة مثل أمراض القلب أو الكلى، فقدان البصر، وضعف تدفق الدورة الدموية في الذراعين والساقين.</p><p dir="RTL">يعمل <strong>ديزيروجا</strong><strong><sup>&reg; </sup></strong>عن طريق التخلص من الكمية الزائدة من السكر في الجسم. وقد يساعد أيضا في الوقاية من أمراض القلب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب</strong><strong> </strong><strong>عدم</strong><strong> </strong><strong>تناول</strong> <strong>ديزيروجا</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>في</strong><strong> </strong><strong>الحالات</strong><strong> </strong><strong>التالية</strong><strong>:</strong></p><p dir="RTL">إذا كنت تعاني من تحسس لداباجليفلوزين أو لأي مكونات أخرى في هذا الدواء.</p><p dir="RTL"><strong>الاحتياطات</strong><strong> </strong><strong>والمحاذير</strong></p><p dir="RTL"><strong>اتصل</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>الطبيب</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>أقرب</strong><strong> </strong><strong>مستشفى</strong><strong> </strong><strong>فورا</strong><strong>:</strong></p><p dir="RTL"><strong>الحماض</strong><strong> </strong><strong>الكيتوني</strong><strong> </strong><strong>السكري</strong><strong>:</strong></p><p dir="RTL">إذا كنت مصاب بداء السكري و تعاني من الشعور بالغثيان أو القيء، ألم في المعدة، شعور شديد بالعطش، نفس سريع وعميق، ارتباك، شعور غير معتاد بالنعاس أو التعب، رائحة سكر في النفس، طعم حلو أو معدن في الفم، أو تغير رائحة البول أو العرق أو فقدان سريع للوزن.</p><p dir="RTL">قد تكون الأعراض المذكورة في الأعلى علامة للحماض الكيتوني السكري - وهي مشكلة خطيرة، أحيانا تكون مهددة للحياة قد تحدث لديك عند الإصابة بداء السكري بسبب زيادة مستويات الأجسام الكيتونية في البول أو الدم، والتي يتم الكشف عنها عند القيام بالفحوصات.</p><p dir="RTL">وقد يزداد خطر الإصابة بالحماض الكيتوني السكري عند الصيام لوقت طويل، الإفراط في تناول الكحول، الجفاف، تقليل جرعة الإنسولين بشكل مفاجئ، أو زيادة الحاجة للإنسولين بسبب الخضوع لعملية جراحية كبرى أو مرض خطير.</p><p dir="RTL">عند الخضوع للعلاج باستعمال <strong>ديزيروجا</strong><strong><sup>&reg;</sup></strong>، قد يحدث الحماض الكيتوني السكري حتى وإن كان&nbsp; مستوى السكر لديك في الدم طبيعي.</p><p dir="RTL">إذا كان لديك شك بأنك تعاني من الحماض الكيتوني السكري، اتصل مع الطبيب أو أقرب مستشفى فورا ولا تتناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحدث</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>طبيبك،</strong><strong> </strong><strong>الصيدلي</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>الممرض</strong><strong> </strong><strong>قبل</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>ديزيروجا</strong><strong><sup>&reg; </sup></strong><strong>في</strong><strong> </strong><strong>الحالات</strong><strong> </strong><strong>التالية</strong><strong>:</strong></p><p dir="RTL">إذا كنت مصاب بالنوع الأول من داء السكري &ndash; وهو النوع الذي يبدأ عادة عندما تكون صغيرا في العمر ولا ينتج الجسم أي كمية من الإنسولين.</p><p dir="RTL">إذا كنت مصاب بداء السكري وتعاني من مشكلة في الكلى &ndash; قد يطلب طبيبك تناول دواء إضافي أو مختلف لضبط مستوى السكر في الدم.</p><p dir="RTL">إذا كنت تعاني من مشكلة في الكبد &ndash; قد يبدأ طبيبك العلاج باستعمال جرعة أقل.</p><p dir="RTL">إذا كنت تستعمل أدوية لخفض ضغط الدم (الأدوية المضادة لارتفاع ضغط الدم) وأصبت سابقا بانخفاض ضغط الدم.</p><p dir="RTL">إذا كانت مستويات السكر في الدم مرتفعة جدا والتي قد تسبب الجفاف (فقدان كمية كبيرة من سوائل الجسم). العلامات المحتملة للجفاف مذكورة في قسم رقم 4. أخبر طبيبك قبل بدء تناول <strong>ديزيروجا</strong><strong><sup>&reg;</sup></strong> إذا كنت تعاني من أي من هذه العلامات.</p><p dir="RTL">إذا كنت تعاني أو حصل لديك الشعور بالغثيان، قيء أو حمى أو كنت لا تستطيع تناول الطعام أو الشرب. هذه الحالات قد تسبب الجفاف. قد يطلب منك الطبيب التوقف عن تناول <strong>ديزيروجا</strong><strong><sup>&reg; </sup></strong>إلى أن تشفى للوقاية من حدوث الجفاف.</p><p dir="RTL">إذا كنت تصاب غالبا بالتهابات الجهاز البولي.</p><p dir="RTL">إذا كان أي مما ذكر في الأعلى ينطبق عليك (أو إذا كنت غير متأكد)، تحدث مع طبيبك، الصيدلي أو الممرض قبل تناول <strong>ديزيروجا</strong><strong><sup>&reg;</sup></strong>.</p><p dir="RTL"><strong>ديزيروجا</strong><strong><sup>&reg; </sup></strong><strong>والعناية</strong><strong> </strong><strong>بالقدم</strong></p><p dir="RTL">إذا كنت تعاني من داء السكري، من الضروري مراقبة صحة القدمين بشكل منتظم والالتزام بأي نصيحة أخرى تتعلق بالعناية بالقدم يقدمها لك أخصائي الرعاية الصحية.</p><p dir="RTL"><strong>وظيفة</strong><strong> </strong><strong>الكلى</strong></p><p dir="RTL">إذا كنت تعاني من داء السكري، يجب التأكد من صحة الكليتين قبل بدء تناول هذا الدواء أو خلال فترة تناوله.</p><p dir="RTL"><strong>الجلوكوز</strong><strong> </strong><strong>في</strong><strong> </strong><strong>البول</strong></p><p dir="RTL">بسبب طريقة عمل <strong>ديزيروجا</strong><strong><sup>&reg;</sup></strong>، ستكون نتيجة فحص السكر في البول إيجابية خلال فترة تناول هذا الدواء.</p><p dir="RTL"><strong>الأطفال</strong><strong> </strong><strong>والمراهقون</strong></p><p dir="RTL">لا يوصى باستعمال <strong>ديزيروجا</strong><strong><sup>&reg; </sup></strong>للأطفال والمراهقين الذين تقل أعمارهم عن 18 عام، وذلك لأنه لم يتم دراسته على هؤلاء المرضى.</p><p dir="RTL"><strong>الأدوية</strong><strong> </strong><strong>الأخرى</strong><strong> </strong><strong>و</strong><strong> </strong><strong>ديزيروجا</strong><strong><sup>&reg;</sup></strong></p><p dir="RTL">أخبر طبيبك، الصيدلي أو الممرض إذا كنت تتناول، تناولت مؤخرا أو من الممكن أن تتناول أي أدوية أخرى.</p><p dir="RTL"><strong>أخبر</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>بشكل</strong><strong> </strong><strong>خاص</strong><strong>:</strong></p><p dir="RTL">إذا كنت تتناول دواء يستعمل للتخلص من الماء في الجسم (مدر للبول).</p><p dir="RTL">إذا كنت تعاني من النوع الثاني من داء السكري وكنت تتناول أدوية أخرى تقلل من كمية السكر في الدم مثل الإنسولين أو الأدوية التي تنتمي إلى مجموعة السلفونيل يوريا. قد يقلل الطبيب جرعة الأدوية الأخرى هذه، للوقاية من حدوث انخفاض مستويات السكر في الدم.</p><p dir="RTL"><strong>الحمل</strong><strong> </strong><strong>والرضاعة</strong><strong> </strong><strong>الطبيعية</strong></p><p dir="RTL">إذا كنت حامل أو مرضعة، تعتقدين بأنك حامل أو تخططين للحمل، استشيري طبيبك أو الصيدلي قبل تناول هذا الدواء. يجب التوقف عن تناول هذا الدواء في حال حصول الحمل، حيث أنه لا يوصى باستعماله خلال الثلث الثاني والثالت من الحمل. تحدث مع طبيبك عن أفضل طريقة لضبط مستوى السكر في الدم خلال فترة الحمل.</p><p dir="RTL">تحدث مع طبيبك إذا كنت ترغبين بالإرضاع أو إذا كنت ترضعين قبل تناول هذا الدواء. لا تستعملي <strong>ديزيروجا</strong><strong><sup>&reg;</sup></strong> إذا كنت مرضعة. من غير المعروف إذا كان هذا الدواء يفرز في حليب الثدي.</p><p dir="RTL"><strong>القيادة</strong><strong> </strong><strong>واستخدام</strong><strong> </strong><strong>الآلات</strong></p><p dir="RTL">لا يؤثر <strong>ديزيروجا</strong><strong><sup>&reg;</sup></strong> على القدرة على القيادة و استخدام الآلات أو قد يكون له تأثير ضئيل. إن تناول هذا الدواء مع الأدوية الأخرى التي تنتمي إلى مجموعة السلفونيل يوريا أو مع الإنسولين قد يسبب انخفاض كبير في مستويات السكر في الدم، والذي قد يسبب أعراض مثل الارتعاش، تعرق و تغير في الرؤية، وقد يؤثر على قدرتك على القيادة واستخدام الآلات.</p><p dir="RTL">إذا شعرت بالدوار خلال فترة تناول <strong>ديزيروجا</strong><strong><sup>&reg;</sup></strong>، تجنب القيادة أو استخدام أي أدوات أو آلات.</p><p dir="RTL"><strong>يحتوي</strong><strong> </strong><strong>ديزيروجا</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>على</strong><strong> </strong><strong>اللاكتوز</strong></p><p dir="RTL">يحتوي <strong>ديزيروجا</strong><strong><sup>&reg;</sup></strong> على اللاكتوز (سكر الحليب). إذا أخبرت من قبل الطبيب بأنك تعاني من عدم القدرة على تحمل بعض أنواع السكريات، اتصل مع طبيبك قبل تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دائما تناول هذا الدواء تماما كما أخبرك طبيبك أو الصيدلي. تأكد من طبيبك أو الصيدلي إذا لم تكن متأكدا.</p><p dir="RTL"><strong>الجرعة</strong><strong> </strong></p><p dir="RTL">تبلغ الجرعة الموصى بها قرص واحد 10 ملغم كل يوم.</p><p dir="RTL">قد يبدأ الطبيب العلاج باستعمال جرعة 5 ملغم إذا كنت تعاني من مشكلة في الكبد.</p><p dir="RTL">سيصف لك الطبيب الجرعة المناسبة.</p><p dir="RTL"><strong>طريقة</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>هذا</strong><strong> </strong><strong>الدواء</strong></p><p dir="RTL">تناول القرص كاملا مع شرب نصف كوب من الماء.</p><p dir="RTL">من الممكن تناول الأقراص مع أو بدون تناول الطعام.</p><p dir="RTL">من الممكن تناول الجرعة في أي وقت من اليوم. لكن، حاول تناولها في نفس الوقت من كل يوم. هذا سيساعدك في تذكر تناولها.</p><p dir="RTL">قد يقوم الطبيب بوصف <strong>ديزيروجا</strong><strong><sup>&reg; </sup></strong>مع الأدوية الأخرى. تذكر بأن تتناول الأدوية الأخرى هذه كما أخبرك الطبيب. هذا سيساعد في الحصول على أفضل النتائج لصحتك.</p><p dir="RTL">قد يساعد اتباع نظام غذائي وممارسة التمرينات الرياضية في استهلاك سكر الدم من قبل الجسم بطريقة أفضل. إذا كنت تعاني من داء السكري، من الضروري الاستمرار في اتباع نظام غذائي وممارسة التمرينات الرياضية الموصى بها من قبل الطبيب خلال فترة تناول <strong>ديزيروجا</strong><strong><sup>&reg;</sup></strong>.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>تناولت</strong><strong> </strong><strong>ديزيروجا</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>أكثر</strong><strong> </strong><strong>مما</strong><strong> </strong><strong>يجب</strong></p><p dir="RTL">إذا تناولت أقراص <strong>ديزيروجا</strong><strong><sup>&reg; </sup></strong>أكثر مما يجب، تحدث مع طبيبك أو اذهب إلى المستشفى على الفور. اصطحب معك عبوة الدواء.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>نسيت</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>جرعة</strong><strong> </strong><strong>ديزيروجا</strong><strong><sup>&reg;</sup></strong></p><p dir="RTL">يعتمد ما يجب فعله إذا نسيت تناول الجرعة على طول المدة التي تحتاجها إلى أن يحين موعد الجرعة التالية.</p><p dir="RTL">إذا كانت المدة 12 ساعة أو أكثر إلى أن يحين موعد الجرعة التالية، تناول جرعة <strong>ديزيروجا</strong><strong><sup>&reg; </sup></strong>فور تذكرك. بعد ذلك تناول الجرعة التالية في موعدها المعتاد.</p><p dir="RTL">إذا كانت المدة أقل من 12 ساعة إلى أن يحين موعد الجرعة التالية، لا تتناول الجرعة التي نسيتها. بعد ذلك تناول الجرعة التالية في موعدها المعتاد.</p><p dir="RTL">لا تتناول جرعة مضاعفة من <strong>ديزيروجا</strong><strong><sup>&reg; </sup></strong>لتعويض الجرعة التي نسيتها.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>توقفت</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>ديزيروجا</strong><strong><sup>&reg;</sup></strong></p><p dir="RTL">لا تتوقف عن تناول <strong>ديزيروجا</strong><strong><sup>&reg;</sup></strong><sup> </sup>بدون التحدث مع طبيبك أولا. إذا كنت تعاني من داء السكري، قد يزداد مستوى السكر في الدم عند التوقف عن تناول ها الدواء.</p><p dir="RTL">إذ اكان لديك أي أسئلة إضافية عن استعمال هذا الدواء، إسأل طبيبك، الصيدلي أو الممرض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثار جانبية، على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>حصل</strong><strong> </strong><strong>لديك</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>من</strong><strong> </strong><strong>الآثار</strong><strong> </strong><strong>الجانبية</strong><strong> </strong><strong>التالية</strong><strong> </strong><strong>اتصل</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>الطبيب</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>أقرب</strong><strong> </strong><strong>مستشفى</strong><strong> </strong><strong>فورا</strong><strong>:</strong></p><p dir="RTL">حماض كيتوني سكري- هذه الحالة نادرة عند المرضى الذين يعانون من النوع الثاني من داء السكري (قد تؤثر على 1 أو أقل من كل 1000 شخص).</p><p dir="RTL"><strong>علامات</strong><strong> </strong><strong>الحماض</strong><strong> </strong><strong>الكيتوني</strong><strong> </strong><strong>السكري</strong><strong>:</strong></p><p dir="RTL">زيادة مستويات الأجسام الكيتونية في البول أو الدم.</p><p dir="RTL">شعور بالغثيان أو قيء.</p><p dir="RTL">ألم في المعدة.</p><p dir="RTL">شعور شديد بالعطش.</p><p dir="RTL">نفس سريع وعميق.</p><p dir="RTL">ارتباك.</p><p dir="RTL">شعور غير معتاد بالنعاس أو التعب.</p><p dir="RTL">رائحة سكر في النفس، طعم حلو أو معدن في الفم، أو تغير رائحة البول أو العرق.</p><p dir="RTL">فقدان سريع للوزن.</p><p dir="RTL">قد يحدث هذا بغض النظر عن مستوى السكر في الدم. قد يقرر طبيبك التوقف عن العلاج باستعمال <strong>ديزيروجا</strong><strong><sup>&reg; </sup></strong>إما بشكل مؤقت أو دائم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>توقف</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>ديزيروجا</strong><strong><sup>&reg; </sup></strong><strong>واستشر</strong><strong> </strong><strong>الطبيب</strong><strong> </strong><strong>فورا</strong><strong> </strong><strong>إذا</strong><strong> </strong><strong>لاحظت</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>من</strong><strong> </strong><strong>الآثار</strong><strong> </strong><strong>الجانبية</strong><strong> </strong><strong>الخطيرة</strong><strong> </strong><strong>التالية</strong><strong>:</strong></p><p dir="RTL">التهاب الجهاز البولي، لوحظت بشكل شائع (قد تؤثر على 1 أو أقل من كل 10 أشخاص).</p><p dir="RTL"><strong>علامات</strong><strong> </strong><strong>التهاب</strong><strong> </strong><strong>الجهاز</strong><strong> </strong><strong>البولي</strong><strong> </strong><strong>الحاد</strong><strong>:</strong></p><p dir="RTL">حمى و/أو قشعريرة.</p><p dir="RTL">شعور بالحرقة عند التبول.</p><p dir="RTL">ألم في الظهر أو الجنب.</p><p dir="RTL">على الرغم من أن هذا الأثر الجانبي غير شائع، أخبر طبيبك على الفور إذا لاحظت وجود دم في البول.</p><p dir="RTL"><strong>اتصل</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>في</strong><strong> </strong><strong>أقرب</strong><strong> </strong><strong>وقت</strong><strong> </strong><strong>ممكن</strong><strong> </strong><strong>إذا</strong><strong> </strong><strong>كنت</strong><strong> </strong><strong>تعاني</strong><strong> </strong><strong>من</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>من</strong><strong> </strong><strong>الآثار</strong><strong> </strong><strong>الجانبية</strong><strong> </strong><strong>التالية</strong><strong>: </strong></p><p dir="RTL">انخفاض مستويات السكر في الدم، لوحظ بشكل شائع جدا (قد تؤثر على أكثر من 1 من كل 10 أشخاص) عند المرضى الذين يعانون من داء السكري ويتناولون هذا الدواء مع أحد الأدوية التي تنتمي إلى مجموعة السلفونيل يوريا أو الإنسولين.</p><p dir="RTL"><strong>علامات</strong><strong> </strong><strong>انخفاض</strong><strong> </strong><strong>سكر</strong><strong> </strong><strong>الدم</strong><strong>:</strong></p><p dir="RTL">ارتعاش، تعرق، شعور بالقلق الشديد، نبضات قلب سريعة.</p><p dir="RTL">شعور بالجوع، صداع، تغير في الرؤية.</p><p dir="RTL">تغير في المزاج أو شعور بالارتباك.</p><p dir="RTL">سيخبرك طبيبك عن كيفية علاج انخفاض مستويات سكر الدم وعن الإجراءات التي يجب اتباعها عند حصول أي من العلامات المذكورة في الأعلى.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>أخرى</strong><strong> </strong><strong>عند</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>داباجليفلوزين</strong><strong>:</strong></p><p dir="RTL"><strong>شائعة</strong></p><p dir="RTL">التهابات تناسلية (القلاع) في القضيب أو المهبل (قد تتضمن العلامات هياج، حكة، إفرازات أو رائحة غير طبيعية).</p><p dir="RTL">ألم في الظهر.</p><p dir="RTL">إخراج كمية من البول أكبر من المعتاد أو تكرار الحاجة إلى التبول أكثر من المعتاد.</p><p dir="RTL">تغيرات في كمية الكوليستيرول أو الدهون في الدم (تظهر خلال الفحوصات).</p><p dir="RTL">زيادة كمية خلايا الدم الحمراء في الدم (تظهر خلال الفحوصات).</p><p dir="RTL">انخفاض في التصفية الكلوية للكرياتينين (تظهر خلال الفحوصات) في بداية العلاج.</p><p dir="RTL">الشعور بالدوار.</p><p dir="RTL">طفح.</p><p dir="RTL"><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>غير</strong><strong> </strong><strong>شائعة</strong><strong> (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> 1 </strong><strong>أو</strong><strong> </strong><strong>أقل</strong><strong> </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 100 </strong><strong>شخص</strong><strong>):</strong></p><p dir="RTL">فقدان كمية كبيرة جدا من السوائل من الجسم (الجفاف، قد تتضمن العلامات جفاف شديد في الفم أو لزوجة، إخراج كمية قليلة من البول أو انعدامه أو نبضات قب سريعة).</p><p dir="RTL">شعور بالعطش.</p><p dir="RTL">إمساك.</p><p dir="RTL">الاستيقاظ من النوم ليلا للتبول.</p><p dir="RTL">جفاف الفم.</p><p dir="RTL">انخفاض الوزن.</p><p dir="RTL">زيادة مستوى الكرياتينين (تظهر خلال فحوصات الدم المخبرية) في بداية العلاج.</p><p dir="RTL">زيادة اليوريا (تظهر خلال فحوصات الدم المخبرية).</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>حصل</strong><strong> </strong><strong>لديك</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>آثار</strong><strong> </strong><strong>جانبية،</strong><strong> </strong><strong>تحدث</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>الصيدلي</strong><strong>. </strong><strong>هذا</strong><strong> </strong><strong>يتضمن</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>غير</strong><strong> </strong><strong>مذكورة</strong><strong> </strong><strong>في</strong><strong> </strong><strong>هذه</strong><strong> </strong><strong>النشرة</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ بعيدا عن متناول الأطفال و نظرهم.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكورعلى الشريط، الملصق و العلبة الخارجية.</p><p dir="RTL">تاريخ الانتهاء يشير إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL"><strong>ديزيروجا</strong><strong><sup>&reg;</sup></strong> أقراص: يحفظ في درجة حرارة دون 30 &deg;م.</p><p dir="RTL">يجب أن لا يتم التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. وسوف تساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ماذا</strong><strong> </strong><strong>تحتوي</strong><strong> </strong><strong>أقراص</strong><strong> </strong><strong>ديزيروجا</strong><strong><sup>&reg;</sup></strong><strong> </strong></p><p dir="RTL">المادة الفعالة هي داباجليفلوزين.</p><p dir="RTL">المكونات الأخرى هي لاكتوز أحادي الهيدرات، ميكروكريستالين سيليلوز، كروسبوفيدون، سيليكا غروية لا مائية، ستيرات المغنيسيوم، مسحوق أوبادري II أصفر (بولي فينيل الكحول، ثاني أكسيد التيتانيوم، ماكروجول/بولي إيثيلين جلايكول، تلك، أكسيد الحديد الأصفر).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف</strong><strong> </strong><strong>تبدو</strong><strong> </strong><strong>أقراص</strong><strong> </strong><strong>ديزيروجا</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>و</strong><strong> </strong><strong>ما</strong><strong> </strong><strong>هي</strong><strong> </strong><strong>محتويات</strong><strong> </strong><strong>العلبة</strong></p><p dir="RTL"><strong>أقراص</strong><strong> </strong><strong>ديزيروجا</strong><strong><sup>&reg;</sup></strong><strong> 10 </strong><strong>ملغم</strong><strong>: </strong>أقراص مغلفة ألماسية الشكل ذات لون أصفر، محدبة الوجهين، ذات حواف غير حادة، محفور على أحد الأوجه C37، معبأة في أشرطة ألومنيوم/ألومنيوم، معدة للاستعمال عن طريق الفم.</p><p dir="RTL"><strong>حجم</strong><strong> </strong><strong>العبوة</strong><strong>:</strong> 28 قرص مغلف.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مدينة الدواء للصناعات الدوائية - المملكة العربية السعودية.</p><p dir="RTL">المدينة الصناعية الأولى، المرحلة الخامسة، جدة - المملكة العربية السعودية.</p><p dir="RTL">هاتف: 00966920003288</p><p dir="RTL">جوال: 00966555786968</p><p dir="RTL">ص.ب: 4072 - جدة 22429</p><p dir="RTL">بريد الكتروني: info@medcitypharma.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            07/2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dezeroga® 10 mg Film Coated Tablets.
Dapagliflozin 10mg Film Coated Tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dezeroga® 10 mg: Each film coated tablet contains dapagliflozin propanediol equivalent to 10 mg dapagliflozin. 

For a full list of excipients: see section 6.1

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film Coated Tablets.

Dezeroga® 10 mg: Yellow diamond biconvex beveled edge film coated tablet engraved with C37 on one face and plain on the other face, presented in Alu/Alu blisters, intended for oral use.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Type 2 diabetes mellitus</u></p><p><strong>Dezeroga<sup>&reg; </sup></strong>is indicated in adults for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise</p><p>- As monotherapy when metformin is considered inappropriate due to intolerance.</p><p>- In addition to other medicinal products for the treatment of type 2 diabetes.</p><p>For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><em><u>Type 2 diabetes mellitus</u></em></p><p>The recommended dose is 10 mg dapagliflozin once daily.</p><p>When dapagliflozin is used in combination with insulin or an insulin secretagogue, such as a sulphonylurea, a lower dose of insulin or insulin secretagogue may be considered to reduce the risk of hypoglycaemia (see sections 4.5 and 4.8).</p><p><strong>Special populations</strong></p><p><strong>Renal impairment </strong></p><p>No dose adjustment is required based on renal function. Due to limited experience, it is not recommended to initiate treatment with dapagliflozin in patients with GFR less than 25 mL/min. In patients with type 2 diabetes mellitus, the glucose lowering efficacy of dapagliflozin is reduced when the glomerular filtration rate (GFR) is less than 45 mL/min and is likely absent in patients with severe renal impairment. Therefore, if GFR falls below 45 mL/min, additional glucose lowering treatment should be considered in patients with type 2 diabetes mellitus if further glycaemic control is needed.</p><p><strong>Hepatic impairment</strong></p><p>No dosage adjustment is necessary for patients with mild or moderate hepatic impairment. In patients with severe hepatic impairment, a starting dose of 5&nbsp;mg is recommended. If well tolerated, the dose may be increased to 10&nbsp;mg (see sections&nbsp;4.4 and 5.2).</p><p>&nbsp;</p><p><strong>Elderly (&ge;&nbsp;65&nbsp;years)</strong></p><p>No dosage adjustment is recommended based on age.</p><p><strong>&nbsp;</strong></p><p><strong>Paediatric population</strong></p><p>The safety and efficacy of dapagliflozin in children aged 0&nbsp;to&nbsp;&lt;&nbsp;18&nbsp;years have not yet been established. No data are available.</p><p><u>&nbsp;</u></p><p><strong><u>Method of administration</u></strong></p><p><strong>Dezeroga<sup>&reg; </sup></strong>can be taken orally once daily at any time of day with or without food. Tablets are to be swallowed whole.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Renal impairment</strong></p><p>Due to limited experience, it is not recommended to initiate treatment with dapagliflozin in patients with GFR less than 25 mL/min. The glucose lowering efficacy of dapagliflozin is dependent on renal function, and is reduced in patients with GFR less than 45 mL/min and is likely absent in patients with severe renal impairment (see sections 4.2, 5.1 and 5.2). In one study in patients with type 2 diabetes mellitus with moderate renal impairment (GFR less than 60 mL/min), a higher proportion of patients treated with dapagliflozin had adverse reactions of increase in creatinine, phosphorus, parathyroid hormone (PTH) and hypotension, compared with placebo.</p><p><strong>Hepatic impairment</strong></p><p>There is limited experience in clinical trials in patients with hepatic impairment. Dapagliflozin exposure is increased in patients with severe hepatic impairment (see sections&nbsp;4.2 and 5.2).</p><p><strong>Use in patients at risk for volume depletion and/or&nbsp;hypotension</strong></p><p>Due to its mechanism of action, dapagliflozin increases diuresis which may lead to the modest decrease in blood pressure observed in clinical studies (see section&nbsp;5.1). It may be more pronounced in patients with very high blood glucose concentrations.</p><p>Caution should be exercised in patients for whom a dapagliflozin‑induced drop in blood pressure could pose a risk, such as patients on anti‑hypertensive therapy with a history of hypotension or elderly patients.</p><p>In case of intercurrent conditions that may lead to volume depletion (e.g. gastrointestinal illness), careful monitoring of volume status (e.g. physical examination, blood pressure measurements, laboratory tests including haematocrit&nbsp;and electrolytes) is recommended. Temporary interruption of treatment with dapagliflozin is recommended for patients who develop volume depletion until the depletion is corrected (see section&nbsp;4.8).</p><p><strong>Diabetic ketoacidosis</strong></p><p>Sodium-glucose co-transporter&nbsp;2 (SGLT2) inhibitors should be used with caution in patients with increased risk of diabetic ketoacidosis (DKA). Patients who may be at higher risk of DKA include patients with a low beta‑cell function reserve (e.g. type&nbsp;2 diabetes patients with low C‑peptide or latent autoimmune diabetes in adults (LADA) or patients with a history of pancreatitis), patients with conditions that lead to restricted food intake or severe dehydration, patients for whom insulin doses are reduced and patients with increased insulin requirements due to acute medical illness, surgery or alcohol abuse.</p><p>The risk of diabetic ketoacidosis must be considered in the event of non-specific symptoms such as nausea, vomiting, anorexia, abdominal pain, excessive thirst, difficulty breathing, confusion, unusual fatigue or sleepiness. Patients should be assessed for ketoacidosis immediately if these symptoms occur, regardless of blood glucose level.</p><p>Before initiating dapagliflozin, factors in the patient history that may predispose to ketoacidosis should be considered.</p><p>Treatment should be interrupted in patients who are hospitalised for major surgical procedures or acute serious medical illnesses. In both cases, treatment with dapagliflozin may be restarted once the patient&rsquo;s condition has stabilised.</p><p><strong>Type 2 diabetes mellitus</strong></p><p>Rare cases of DKA, including life-threatening and fatal cases, have been reported in patients treated with SGLT2 inhibitors, including dapagliflozin. In a number of cases, the presentation of the condition was atypical with only moderately increased blood glucose values, below 14&nbsp;mmol/L (250&nbsp;mg/dL).</p><p>In patients where DKA is suspected or diagnosed, dapagliflozin treatment should be stopped immediately.</p><p>Restarting SGLT2 inhibitor treatment in patients experiencing a DKA while on SGLT2 inhibitor treatment is not recommended, unless another clear precipitating factor is identified and resolved.</p><p><strong>Type 1 diabetes mellitus</strong></p><p>In type&nbsp;1 diabetes mellitus studies with dapagliflozin, DKA was reported with common frequency. Dapagliflozin should not be used for treatment of patients with type&nbsp;1 diabetes.</p><p><strong>Urinary tract infections</strong></p><p>Urinary glucose excretion may be associated with an increased risk of urinary tract infection; therefore, temporary interruption of dapagliflozin should be considered when treating pyelonephritis or urosepsis.</p><p><strong>Elderly (&ge;&nbsp;65&nbsp;years)</strong></p><p>Elderly patients may be at a greater risk for volume depletion and are more likely to be treated with diuretics.</p><p>Elderly patients are more likely to have impaired renal function, and/or to be treated with anti‑hypertensive medicinal products that may cause changes in renal function such as angiotensin‑converting enzyme inhibitors (ACE‑I) and angiotensin&nbsp;II type&nbsp;1 receptor blockers (ARB). The same recommendations for renal function apply to elderly patients as to all patients (see sections&nbsp;4.2, 4.4, 4.8 and 5.1).</p><p><strong>Cardiac failure</strong></p><p>Experience in clinical studies with dapagliflozin in NYHA&nbsp;class&nbsp;IV is limited.</p><p><strong>Lower limb amputations</strong></p><p>An increase in cases of lower limb amputation (primarily of the toe) has been observed in long-term, clinical studies in type&nbsp;2 diabetes mellitus with another SGLT2 inhibitor. It is unknown whether this constitutes a class effect. it is important to counsel patients with diabetes on routine preventative foot care.&nbsp;</p><p><strong>Urine laboratory assessments</strong></p><p>Due to its mechanism of action, patients taking <strong>Dezeroga<sup>&reg; </sup></strong>will test positive for glucose in their urine.</p><p><strong>Lactose</strong></p><p>The tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption should not take this medicinal product.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacodynamic interactions</strong></p><p><strong>Diuretics</strong></p><p>Dapagliflozin may add to the diuretic effect of thiazide and loop diuretics and may increase the risk of dehydration and hypotension (see section&nbsp;4.4).</p><p>&nbsp;</p><p><strong>Insulin and insulin secretagogues</strong></p><p>Insulin and insulin secretagogues, such as sulphonylureas, cause hypoglycaemia. Therefore, a lower dose of insulin or an insulin secretagogue may be required to reduce the risk of hypoglycaemia when used in combination with dapagliflozin&nbsp;in patients with type 2 diabetes mellitus (see sections&nbsp;4.2 and 4.8).</p><p><strong>&nbsp;</strong></p><p><strong>Pharmacokinetic interactions</strong></p><p>The metabolism of dapagliflozin is primarily via glucuronide conjugation mediated by UDP&nbsp;glucuronosyltransferase&nbsp;1A9 (UGT1A9).</p><p>&nbsp;</p><p>In&nbsp;in vitro&nbsp;studies, dapagliflozin neither inhibited cytochrome&nbsp;P450&nbsp;(CYP)&nbsp;1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, nor induced CYP1A2, CYP2B6 or CYP3A4. Therefore, dapagliflozin is not expected to alter the metabolic clearance of coadministered medicinal products that are metabolised by these enzymes.</p><p>&nbsp;</p><p><strong>Effect of other medicinal products on dapagliflozin</strong></p><p>Interaction studies conducted in healthy subjects, using mainly a single‑dose design, suggest that the pharmacokinetics of dapagliflozin are not altered by metformin, pioglitazone, sitagliptin, glimepiride, voglibose, hydrochlorothiazide, bumetanide, valsartan, or simvastatin.</p><p>&nbsp;</p><p>Following coadministration of dapagliflozin with rifampicin (an inducer of various active transporters and drug‑metabolising enzymes) a 22% decrease in dapagliflozin systemic exposure&nbsp;(AUC) was observed, but with no clinically meaningful effect on 24‑hour urinary glucose excretion. No dose adjustment is recommended. A clinically relevant effect with other inducers (e.g. carbamazepine, phenytoin, phenobarbital) is not expected.</p><p>&nbsp;</p><p>Following coadministration of dapagliflozin with mefenamic&nbsp;acid (an inhibitor of UGT1A9), a 55% increase in dapagliflozin systemic exposure was seen, but with no clinically meaningful effect on 24‑hour urinary glucose excretion. No dose adjustment is recommended.</p><p>&nbsp;</p><p><strong>Effect of dapagliflozin on other medicinal products</strong></p><p>In interaction studies conducted in healthy subjects, using mainly a single‑dose design, dapagliflozin did not alter the pharmacokinetics of metformin, pioglitazone, sitagliptin, glimepiride, hydrochlorothiazide, bumetanide, valsartan, digoxin (a P‑gp substrate) or warfarin (S‑warfarin, a CYP2C9 substrate), or the anticoagulatory effects of warfarin as measured by INR. Combination of a single dose of dapagliflozin 20&nbsp;mg and simvastatin (a CYP3A4 substrate) resulted in a 19% increase in AUC of simvastatin and 31% increase in AUC of simvastatin acid. The increase in simvastatin and simvastatin acid exposures are not considered clinically relevant.</p><p>&nbsp;</p><p><strong>Interference with 1,5-anhydroglucitol (1,5-AG) assay</strong></p><p>Monitoring glycaemic control with 1,5-AG assay is not recommended as measurements of 1,5-AG are unreliable in assessing glycaemic control in patients taking SGLT2 inhibitors. Use of alternative methods to monitor glycaemic control is advised.</p><p>&nbsp;</p><p><strong>Paediatric population</strong></p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong></p><p>There are no data from the use of dapagliflozin in pregnant women. Studies in rats have shown toxicity to the developing kidney in the time period corresponding to the second and third trimesters of human pregnancy (see section&nbsp;5.3). Therefore, the use of dapagliflozin is not recommended during the second and third trimesters of pregnancy.</p><p>When pregnancy is detected, treatment with dapagliflozin should be discontinued.</p><p><strong>Breast‑feeding</strong></p><p>It is unknown whether dapagliflozin and/or its metabolites are excreted in human milk. Available pharmacodynamic/toxicological data in animals have shown excretion of dapagliflozin/metabolites in milk, as well as pharmacologically-mediated effects in nursing offspring (see section&nbsp;5.3). A risk to the newborns/infants cannot be excluded. Dapagliflozin should not be used while breast‑feeding.</p><p>&nbsp;</p><p><strong>Fertility</strong></p><p>The effect of dapagliflozin on fertility in humans has not been studied. In male and female rats, dapagliflozin showed no effects on fertility at any dose tested.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Dezeroga<sup>&reg; </sup></strong>has no or negligible influence on the ability to drive and use machines. Patients should be alerted to the risk of hypoglycaemia when dapagliflozin is used in combination with a sulphonylurea or insulin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p><em><u>Type 2 diabetes mellitus</u></em></p><p>In the clinical studies in type 2 diabetes, more than 15,000 patients have been treated with dapagliflozin.</p><p>The primary assessment of safety and tolerability was conducted in a pre-specified pooled analysis of 13 short-term (up to 24 weeks) placebo-controlled studies with 2,360 subjects treated with dapagliflozin 10 mg and 2,295 treated with placebo.</p><p>In the dapagliflozin cardiovascular outcomes study in type 2 diabetes mellitus (DECLARE study, see section 5.1), 8,574 patients received dapagliflozin 10 mg and 8,569 received placebo for a median exposure time of 48 months. In total, there were 30,623 patient-years of exposure to dapagliflozin.</p><p>The most frequently reported adverse reactions across the clinical studies were genital infections.</p><p><u>Tabulated list of adverse reactions</u></p><p>The following adverse reactions have been identified in the placebo-controlled clinical studies and postmarketing surveillance. None were found to be dose-related. Adverse reactions listed below are classified according to frequency and system organ class (SOC). Frequency categories are defined according to the following convention: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000), and not known (cannot be estimated from the available data).</p><p><strong>Table 1. Adverse reactions in placebo-controlled clinical studies<sup>a</sup>&nbsp;and postmarketing experience</strong></p><table border="1" cellspacing="0" cellpadding="0" align="left" style="width:0px"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Very common</strong></p></td><td style="vertical-align:top"><p><strong>Common*</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon**</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Infections and infestations</em></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Vulvovaginitis, balanitis and related genital infections<sup>*,b,c</sup></p><p>Urinary tract infection<sup>*,b,d</sup></p></td><td style="vertical-align:top"><p>Fungal infection**</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><em>Metabolism and nutrition disorders</em></p></td><td style="vertical-align:top"><p>Hypoglycaemia (when used with SU or insulin)<sup>b</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Volume depletion<sup>b,e</sup></p><p>Thirst**</p></td><td style="vertical-align:top"><p>Diabetic ketoacidosis (when used in type 2 diabetes mellitus)<sup>b,i,k</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Nervous system disorders</em></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><em>Gastrointestinal disorders</em></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Constipation**</p><p>Dry mouth**</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><em>Skin and subcutaneous tissue disorders</em></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rash<sup>j</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><em>Musculoskeletal and connective tissue disorders</em></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Back pain*</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><em>Renal and urinary disorders</em></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Dysuria</p><p>Polyuria<sup>*,f</sup></p></td><td style="vertical-align:top"><p>Nocturia**</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><em>Reproductive system and breast disorders</em></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Vulvovaginal pruritus**</p><p>Pruritus genital**</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><em>Investigations</em></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Haematocrit increased<sup>g</sup></p><p>Creatinine renal clearance decreased during initial treatment<sup>b</sup></p><p>Dyslipidaemia<sup>h</sup></p></td><td style="vertical-align:top"><p>Blood creatinine increased during initial treatment<sup>**,b</sup></p><p>Blood urea increased**</p><p>Weight decreased**</p></td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><sup>a</sup>The table shows up to 24-week (short-term) data regardless of glycaemic rescue.</p><p><sup>b</sup>See corresponding subsection below for additional information.</p><p><sup>c</sup>Vulvovaginitis, balanitis and related genital infections includes, e.g. the predefined preferred terms: vulvovaginal mycotic infection, vaginal infection, balanitis, genital infection fungal, vulvovaginal candidiasis, vulvovaginitis, balanitis candida, genital candidiasis, genital infection, genital infection male, penile infection, vulvitis, vaginitis bacterial, vulval abscess.</p><p><sup>d</sup>Urinary tract infection includes the following preferred terms, listed in order of frequency reported: urinary tract infection, cystitis, Escherichia urinary tract infection, genitourinary tract infection, pyelonephritis, trigonitis, urethritis, kidney infection and prostatitis.</p><p><sup>e</sup>Volume depletion includes, e.g. the predefined preferred terms: dehydration, hypovolaemia, hypotension.</p><p><sup>f</sup>Polyuria includes the preferred terms: pollakiuria, polyuria, urine output increased.</p><p><sup>g</sup>Mean changes from baseline in haematocrit were 2.30% for dapagliflozin 10 mg versus-0.33% for placebo. Haematocrit values &gt;55% were reported in 1.3% of the subjects treated with dapagliflozin 10 mg versus 0.4% of placebo subjects.</p><p><sup>h</sup>Mean percent change from baseline for dapagliflozin 10 mg versus placebo, respectively, was: total cholesterol 2.5% versus 0.0%; HDL cholesterol 6.0% versus 2.7%; LDL cholesterol 2.9% versus -1.0%; triglycerides &ndash;2.7% versus -0.7%.</p><p><sup>i</sup>See section 4.4.</p><p><sup>j</sup>Adverse reaction was identified through postmarketing surveillance. Rash includes the following preferred terms, listed in order of frequency in clinical studies: rash, rash generalised, rash pruritic, rash macular, rash maculo-papular, rash pustular, rash vesicular, and rash erythematous. In active- and placebo-controlled clinical studies (dapagliflozin, N=5936, All control, N=3403), the frequency of rash was similar for dapagliflozin (1.4 %) and all control (1.4%), respectively.</p><p><sup>k</sup>Reported in the cardiovascular outcomes study in patients with type 2 diabetes (DECLARE). Frequency is based on annual rate.</p><p>*Reported in &ge; 2% of subjects and &ge; 1% more and at least 3 more subjects treated with dapagliflozin 10 mg compared to placebo.</p><p>**Reported by the investigator as possibly related, probably related or related to study treatment and reported in &ge; 0.2% of subjects and &ge; 0.1% more and at least 3 more subjects treated with dapagliflozin 10 mg compared to placebo.</p><p><u>Description of selected adverse reactions</u></p><p><em><u>Vulvovaginitis, balanitis and related genital infections</u></em></p><p>In the 13-study safety pool, vulvovaginitis, balanitis and related genital infections were reported in 5.5% and 0.6% of subjects who received dapagliflozin 10 mg and placebo, respectively. Most infections were mild to moderate, and subjects responded to an initial course of standard treatment and rarely resulted in discontinuation from dapagliflozin treatment. These infections were more frequent in females (8.4% and 1.2% for dapagliflozin and placebo, respectively), and subjects with a prior history were more likely to have a recurrent infection.</p><p>In the DECLARE study, the numbers of patients with serious adverse events of genital infections were few and balanced: 2 patients in each of the dapagliflozin and placebo groups.</p><p>In the DAPA-HF study, no patient reported serious adverse events of genital infections in the dapagliflozin group and one in the placebo group. There were 7 (0.3%) patients with adverse events leading to discontinuations due to genital infections in the dapagliflozin group and none in the placebo group.</p><p><em><u>Hypoglycaemia</u></em></p><p>The frequency of hypoglycaemia depended on the type of background therapy used in the clinical studies in diabetes mellitus.</p><p>For studies of dapagliflozin in monotherapy, as add-on to metformin or as add-on to sitagliptin (with or without metformin), the frequency of minor episodes of hypoglycaemia was similar (&lt; 5%) between treatment groups, including placebo up to 102 weeks of treatment. Across all studies, major events of hypoglycaemia were uncommon and comparable between the groups treated with dapagliflozin or placebo. Studies with add-on sulphonylurea and add-on insulin therapies had higher rates of hypoglycaemia (see section 4.5).</p><p>In an add-on to glimepiride study, at weeks 24 and 48, minor episodes of hypoglycaemia were reported more frequently in the group treated with dapagliflozin 10 mg plus glimepiride (6.0% and 7.9%, respectively) than in the placebo plus glimepiride group (2.1% and 2.1%, respectively).</p><p>In an add-on to insulin study, episodes of major hypoglycaemia were reported in 0.5% and 1.0% of subjects treated with dapagliflozin 10 mg plus insulin at weeks 24 and 104, respectively, and in 0.5% of subjects treated with placebo plus insulin groups at weeks 24 and 104. At weeks 24 and 104, minor episodes of hypoglycaemia were reported, respectively, in 40.3% and 53.1% of subjects who received dapagliflozin 10 mg plus insulin and in 34.0% and 41.6% of the subjects who received placebo plus insulin.</p><p>In an add-on to metformin and a sulphonylurea study, up to 24 weeks, no episodes of major hypoglycaemia were reported. Minor episodes of hypoglycaemia were reported in 12.8% of subjects who received dapagliflozin 10 mg plus metformin and a sulphonylurea and in 3.7% of subjects who received placebo plus metformin and a sulphonylurea.</p><p>In the DECLARE study, no increased risk of major hypoglycaemia was observed with dapagliflozin therapy compared with placebo. Major events of hypoglycaemia were reported in 58 (0.7%) patients treated with dapagliflozin and 83 (1.0%) patients treated with placebo.</p><p>In the DAPA-HF study, major events of hypoglycaemia were reported in 4 (0.2%) patients in both the dapagliflozin and placebo treatment groups and observed only in patients with type 2 diabetes mellitus.</p><p><em><u>Volume depletion</u></em></p><p>In the 13-study safety pool, reactions suggestive of volume depletion (including, reports of dehydration, hypovolaemia or hypotension) were reported in 1.1% and 0.7% of subjects who received dapagliflozin 10 mg and placebo, respectively; serious reactions occurred in &lt; 0.2% of subjects balanced between dapagliflozin 10 mg and placebo (see section 4.4).</p><p>In the DECLARE study, the numbers of patients with events suggestive of volume depletion were balanced between treatment groups: 213 (2.5%) and 207 (2.4%) in the dapagliflozin and placebo groups, respectively. Serious adverse events were reported in 81 (0.9%) and 70 (0.8%) in the dapagliflozin and placebo group, respectively. Events were generally balanced between treatment groups across subgroups of age, diuretic use, blood pressure and angiotensin converting enzyme inhibitors (ACE-I)/angiotensin II type 1 receptor blockers (ARB) use. In patients with eGFR &lt; 60 mL/min/1.73 m<sup>2</sup>&nbsp;at baseline, there were 19 events of serious adverse events suggestive of volume depletion in the dapagliflozin group and 13 events in the placebo group.</p><p>In the DAPA-HF study, the numbers of patients with events suggestive of volume depletion were 170 (7.2%) in the dapagliflozin group and 153 (6.5%) in the placebo group. There were fewer patients with serious events of symptoms suggestive of volume depletion in the dapagliflozin group (23 [1.0%]) compared with the placebo group (38 [1.6%]). Results were similar irrespective of presence of diabetes at baseline and baseline eGFR.</p><p><em><u>Diabetic ketoacidosis in type 2 diabetes mellitus</u></em></p><p>In the DECLARE study, with a median exposure time of 48 months, events of DKA were reported in 27 patients in the dapagliflozin 10 mg group and 12 patients in the placebo group. The events occurred evenly distributed over the study period. Of the 27 patients with DKA events in the dapagliflozin group, 22 had concomitant insulin treatment at the time of the event. Precipitating factors for DKA were as expected in a type 2 diabetes mellitus population (see section 4.4).</p><p>In the DAPA-HF study, events of DKA were reported in 3 patients with type 2 diabetes mellitus in the dapagliflozin group and none in the placebo group.</p><p><em><u>Urinary tract infections</u></em></p><p>In the 13-study safety pool, urinary tract infections were more frequently reported for dapagliflozin 10 mg compared to placebo (4.7% versus 3.5%, respectively; see section 4.4). Most infections were mild to moderate, and subjects responded to an initial course of standard treatment and rarely resulted in discontinuation from dapagliflozin treatment. These infections were more frequent in females, and subjects with a prior history were more likely to have a recurrent infection.</p><p>In the DECLARE study, serious events of urinary tract infections were reported less frequently for dapagliflozin 10 mg compared with placebo, 79 (0.9%) events versus 109 (1.3%) events, respectively.</p><p>In the DAPA-HF study, the numbers of patients with serious adverse events of urinary tract infections were 14 (0.6%) in the dapagliflozin group and 17 (0.7%) in the placebo group. There were 5 (0.2%) patients with adverse events leading to discontinuations due to urinary tract infections in each of the dapagliflozin and placebo groups.</p><p><em><u>Increased creatinine</u></em></p><p>Adverse reactions related to increased creatinine were grouped (e.g. decreased renal creatinine clearance, renal impairment, increased blood creatinine and decreased glomerular filtration rate). In the 13-study safety pool, this grouping of reactions was reported in 3.2% and 1.8% of patients who received dapagliflozin 10 mg and placebo, respectively. In patients with normal renal function or mild renal impairment (baseline eGFR &ge; 60 mL/min/1.73 m<sup>2</sup>) this grouping of reactions were reported in 1.3% and 0.8% of patients who received dapagliflozin 10 mg and placebo, respectively. These reactions were more common in patients with baseline eGFR &ge; 30 and &lt; 60 mL/min/1.73 m<sup>2</sup>&nbsp;(18.5% dapagliflozin 10 mg versus 9.3% placebo).</p><p>Further evaluation of patients who had renal-related adverse events showed that most had serum creatinine changes of &le; 0.5 mg/dL from baseline. The increases in creatinine were generally transient during continuous treatment or reversible after discontinuation of treatment.</p><p>In the DECLARE study, including elderly patients and patients with renal impairment (eGFR less than 60 mL/min/1.73 m<sup>2</sup>), eGFR decreased over time in both treatment groups. At 1 year, mean eGFR was slightly lower, and at 4 years, mean eGFR was slightly higher in the dapagliflozin group compared with the placebo group.</p><p>In the DAPA-HF study, eGFR decreased over time in both the dapagliflozin group and the placebo group. The initial decrease in mean eGFR was -4.3 mL/min/1.73 m<sup>2</sup>&nbsp;in the dapagliflozin group and -1.1 mL/min/1.73 m<sup>2</sup>&nbsp;in the placebo group. At 20 months, change from baseline in eGFR was similar between the treatment groups: -5.3 mL/min/1.73 m<sup>2</sup>&nbsp;for dapagliflozin and -4.5 mL/min/1.73 m<sup>2</sup>&nbsp;for placebo.</p><p>&nbsp;</p><p><strong>To report any side effect</strong>(<strong>s</strong>)<strong>:</strong></p><p><strong>&bull; Saudi Arabia:</strong></p><p>The National Pharmacovigilance Center (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p><strong>&bull; Other GCC States:</strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dapagliflozin did not show any toxicity in healthy subjects at single oral doses up to 500 mg (50 times the maximum recommended human dose). These subjects had detectable glucose in the urine for a dose-related period of time (at least 5 days for the 500 mg dose), with no reports of dehydration, hypotension or electrolyte imbalance, and with no clinically meaningful effect on QTc interval. The incidence of hypoglycaemia was similar to placebo. In clinical studies where once-daily doses of up to 100 mg (10 times the maximum recommended human dose) were administered for 2 weeks in healthy subjects and type 2 diabetes subjects, the incidence of hypoglycaemia was slightly higher than placebo and was not dose-related. Rates of adverse events including dehydration or hypotension were similar to placebo, and there were no clinically meaningful dose-related changes in laboratory parameters, including serum electrolytes and biomarkers of renal function.</p><p>In the event of an overdose, appropriate supportive treatment should be initiated as dictated by the patient&#39;s clinical status. The removal of dapagliflozin by haemodialysis has not been studied.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.1 Pharmacodynamic properties</strong></p><p>Pharmacotherapeutic group: Drugs used in diabetes, sodium-glucose co-transporter 2 (SGLT2) inhibitors, ATC code: A10BK01</p><p><u>Mechanism of action</u></p><p>Dapagliflozin is a highly potent (K<sub>i</sub>: 0.55 nM), selective and reversible inhibitor of SGLT2.</p><p>Inhibition of SGLT2 by dapagliflozin reduces reabsorption of glucose from the glomerular filtrate in the proximal renal tubule with a concomitant reduction in sodium reabsorption leading to urinary excretion of glucose and osmotic diuresis. Dapagliflozin therefore increases the delivery of sodium to the distal tubule which increases tubuloglomerular feedback and reduce intraglomerular pressure. This combined with osmotic diuresis leads to a reduction in volume overload, reduced blood pressure, and lower preload and afterload, which may have beneficial effects on cardiac remodelling and preserve renal function. Other effects include an increase in haematocrit and reduction in body weight. The cardiac and renal benefits of dapagliflozin are not solely dependent on the blood glucose-lowering effect and not limited to patients with diabetes as demonstrated in the DAPA-HF study.</p><p>Dapagliflozin improves both fasting and post-prandial plasma glucose levels by reducing renal glucose reabsorption leading to urinary glucose excretion. This glucose excretion (glucuretic effect) is observed after the first dose, is continuous over the 24-hour dosing interval and is sustained for the duration of treatment. The amount of glucose removed by the kidney through this mechanism is dependent upon the blood glucose concentration and GFR. Thus, in subjects with normal blood glucose and/or low GFR, dapagliflozin has a low propensity to cause hypoglycaemia, as the amount of filtrated glucose is small and can be reabsorbed by SGLT1 and unblocked SGLT2 transporters. Dapagliflozin does not impair normal endogenous glucose production in response to hypoglycaemia. Dapagliflozin acts independently of insulin secretion and insulin action. Improvement in homeostasis model assessment for beta cell function (HOMA beta-cell) has been observed in clinical studies with dapagliflozin.</p><p>The SGLT2 is selectively expressed in the kidney. Dapagliflozin does not inhibit other glucose transporters important for glucose transport into peripheral tissues and is &gt; 1,400 times more selective for SGLT2 versus SGLT1, the major transporter in the gut responsible for glucose absorption.</p><p><u>Pharmacodynamic effects</u></p><p>Increases in the amount of glucose excreted in the urine were observed in healthy subjects and in subjects with type 2 diabetes mellitus following the administration of dapagliflozin. Approximately 70 g of glucose was excreted in the urine per day (corresponding to 280 kcal/day) at a dapagliflozin dose of 10 mg/day in subjects with type 2 diabetes mellitus for 12 weeks. Evidence of sustained glucose excretion was seen in subjects with type 2 diabetes mellitus given dapagliflozin 10 mg/day for up to 2 years.</p><p>This urinary glucose excretion with dapagliflozin also results in osmotic diuresis and increases in urinary volume in subjects with type 2 diabetes mellitus. Urinary volume increases in subjects with type 2 diabetes mellitus treated with dapagliflozin 10 mg were sustained at 12 weeks and amounted to approximately 375 mL/day. The increase in urinary volume was associated with a small and transient increase in urinary sodium excretion that was not associated with changes in serum sodium concentrations.</p><p>Urinary uric acid excretion was also increased transiently (for 3-7 days) and accompanied by a sustained reduction in serum uric acid concentration. At 24 weeks, reductions in serum uric acid concentrations ranged from -48.3 to -18.3 micromoles/L (-0.87 to -0.33 mg/dL).</p><p><u>Clinical efficacy and safety</u></p><p><u>Type 2 diabetes mellitus</u></p><p>Both improvement of glycaemic control and reduction of cardiovascular and renal morbidity and mortality are integral parts of the treatment of type 2 diabetes.</p><p>Fourteen double-blind, randomised, controlled clinical studies were conducted with 7,056 subjects with type 2 diabetes to evaluate the glycaemic efficacy and safety of dapagliflozin; 4,737 subjects in these studies were treated with dapagliflozin. Twelve studies had a treatment period of 24 weeks duration, 8 with long-term extensions ranging from 24 to 80 weeks (up to a total study duration of 104 weeks), one study had a 28-week treatment period, and one study was 52 weeks in duration with long-term extensions of 52 and 104 weeks (total study duration of 208 weeks). Mean duration of diabetes ranged from 1.4 to 16.9 years. Fifty percent (50%) had mild renal impairment and 11% had moderate renal impairment. Fifty-one percent (51%) of the subjects were men, 84% were White, 8% were Asian, 4% were Black and 4% were of other racial groups. Eighty-one percent (81%) of the subjects had a body mass index (BMI) &ge; 27. Furthermore, two 12-week, placebo-controlled studies were conducted in patients with inadequately controlled type 2 diabetes and hypertension.</p><p>A cardiovascular outcomes study (DECLARE) was conducted with dapagliflozin 10 mg compared with placebo in 17,160 patients with type 2 diabetes mellitus with or without established cardiovascular disease to evaluate the effect on cardiovascular and renal events.</p><p><em><u>Glycaemic control</u></em></p><p><em>Monotherapy</em></p><p>A double-blind, placebo-controlled study of 24-week duration (with an additional extension period) was conducted to evaluate the safety and efficacy of monotherapy with dapagliflozin in subjects with inadequately controlled type 2 diabetes mellitus. Once-daily treatment with dapagliflozin resulted in statistically significant (p &lt; 0.0001) reductions in HbA1c compared to placebo (Table 2).</p><p>In the extension period, HbA1c reductions were sustained through week 102 (-0.61%, and -0.17% adjusted mean change from baseline for dapagliflozin 10 mg and placebo, respectively).</p><p><strong>Table 2. Results at week 24 (LOCF<sup>a</sup>) of a placebo-controlled study of dapagliflozin as monotherapy</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:bottom; width:96px">&nbsp;</td><td colspan="2" style="vertical-align:top; width:140px"><p><strong>Monotherapy</strong></p></td></tr><tr><td style="vertical-align:bottom; width:96px">&nbsp;</td><td style="vertical-align:top; width:123px"><p><strong>Dapagliflozin</strong></p><p><strong>10 mg</strong></p></td><td style="vertical-align:top; width:33px"><p><strong>Placebo</strong></p></td></tr><tr><td style="vertical-align:top; width:96px"><p><strong>N<sup>b</sup></strong></p></td><td style="vertical-align:top; width:123px"><p>70</p></td><td style="vertical-align:top; width:33px"><p>75</p></td></tr><tr><td style="vertical-align:top; width:96px"><p><strong>HbA1c (%)</strong></p><p><strong>Baseline (mean)</strong></p><p>Change from baseline<sup>c</sup></p><p>Difference from placebo<sup>c</sup></p><p>(95% CI)</p></td><td style="vertical-align:top; width:123px"><p>&nbsp;</p><p>8.01</p><p>-0.89</p><p>-0.66*</p><p>(-0.96, -0.36)</p></td><td style="vertical-align:top; width:33px"><p>&nbsp;</p><p>7.79</p><p>-0.23</p></td></tr><tr><td style="vertical-align:top; width:96px"><p><strong>Subjects (%) achieving:</strong></p><p><strong>HbA1c &lt; 7%</strong></p><p>Adjusted for baseline</p></td><td style="vertical-align:top; width:123px"><p>&nbsp;</p><p>&nbsp;</p><p>50.8<sup>&sect;</sup></p></td><td style="vertical-align:top; width:33px"><p>&nbsp;</p><p>&nbsp;</p><p>31.6</p></td></tr><tr><td style="vertical-align:top; width:96px"><p><strong>Body weight (kg)</strong></p><p>Baseline (mean)</p><p>Change from baseline<sup>c</sup></p><p>Difference from placebo<sup>c</sup></p><p>(95% CI)</p></td><td style="vertical-align:top; width:123px"><p>&nbsp;</p><p>94.13</p><p>-3.16</p><p>-0.97</p><p>(-2.20, 0.25)</p></td><td style="vertical-align:top; width:33px"><p>&nbsp;</p><p>88.77</p><p>-2.19</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup>LOCF: Last observation (prior to rescue for rescued subjects) carried forward</p><p><sup>b</sup>All randomised subjects who took at least one dose of double-blind study medicinal product during the short-term double-blind period</p><p><sup>c</sup>Least squares mean adjusted for baseline value</p><p>*p-value &lt; 0.0001 versus placebo</p><p><sup>&sect;&nbsp;</sup>Not evaluated for statistical significance as a result of the sequential testing procedure for secondary end points</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Add-on combination therapy</em></p><p>In a 52-week, active-controlled non-inferiority study (with 52- and 104-week extension periods), dapagliflozin was evaluated as add-on therapy to metformin compared with a sulphonylurea (glipizide) as add-on therapy to metformin in subjects with inadequate glycaemic control (HbA1c &gt; 6.5% and &le; 10%). The results showed a similar mean reduction in HbA1c from baseline to week 52, compared to glipizide, thus demonstrating non-inferiority (Table 3). At week 104, adjusted mean change from baseline in HbA1c was -0.32% for dapagliflozin and -0.14% for glipizide. At week 208, adjusted mean change from baseline in HbA1c was -0.10% for dapagliflozin and 0.20% for glipizide. At 52, 104 and 208 weeks, a significantly lower proportion of subjects in the group treated with dapagliflozin (3.5%, 4.3% and 5.0%, respectively) experienced at least one event of hypoglycaemia compared to the group treated with glipizide (40.8%, 47.0% and 50.0%, respectively). The proportion of subjects remaining in the study at week 104 and week 208 was 56.2% and 39.7% for the group treated with dapagliflozin and 50.0% and 34.6% for the group treated with glipizide.</p><p><strong>Table 3. Results at week 52 (LOCF<sup>a</sup>) in an active-controlled study comparing dapagliflozin to glipizide as add-on to metformin</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:bottom"><p><strong>Parameter</strong></p></td><td style="vertical-align:top"><p><strong>Dapagliflozin</strong></p><p><strong>+ metformin</strong></p></td><td style="vertical-align:top"><p><strong>Glipizide</strong></p><p><strong>+ metformin</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>N</strong><sup>b</sup></p></td><td style="vertical-align:top"><p>400</p></td><td style="vertical-align:top"><p>401</p></td></tr><tr><td style="vertical-align:top"><p><strong>HbA1c (%)</strong></p><p>Baseline (mean)</p><p>Change from baseline<sup>c</sup></p><p>Difference from glipizide + metformin<sup>c</sup></p><p>(95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>7.69</p><p>-0.52</p><p>0.00<sup>d</sup></p><p>(-0.11, 0.11)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>7.74</p><p>-0.52</p></td></tr><tr><td style="vertical-align:top"><p><strong>Body weight (kg)</strong></p><p>Baseline (mean)</p><p>Change from baseline<sup>c</sup></p><p>Difference from glipizide + metformin<sup>c</sup></p><p>(95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>88.44</p><p>-3.22</p><p>-4.65*</p><p>(-5.14, -4.17)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>87.60</p><p>1.44</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup>LOCF: Last observation carried forward</p><p><sup>b</sup>Randomised and treated subjects with baseline and at least 1 post-baseline efficacy measurement</p><p><sup>c</sup>Least squares mean adjusted for baseline value</p><p><sup>d</sup>Non-inferior to glipizide + metformin</p><p>*p-value &lt; 0.0001</p></td></tr></tbody></table><p>Dapagliflozin as an add-on with either metformin, glimepiride, metformin and a sulphonylurea, sitagliptin (with or without metformin) or insulin resulted in statistically significant reductions in HbA1c at 24 weeks compared with subjects receiving placebo (p &lt; 0.0001; Tables 4, 5 and 6).</p><p>The reductions in HbA1c observed at week 24 were sustained in add-on combination studies (glimepiride and insulin) with 48-week data (glimepiride) and up to 104-week data (insulin). At week 48 when added to sitagliptin (with or without metformin), the adjusted mean change from baseline for dapagliflozin 10 mg and placebo was -0.30% and 0.38%, respectively. For the add-on to metformin study, HbA1c reductions were sustained through week 102 (-0.78% and 0.02% adjusted mean change from baseline for 10 mg and placebo, respectively). At week 104 for insulin (with or without additional oral glucose-lowering medicinal products), the HbA1c reductions were -0.71% and -0.06% adjusted mean change from baseline for dapagliflozin 10 mg and placebo, respectively. At weeks 48 and 104, the insulin dose remained stable compared to baseline in subjects treated with dapagliflozin 10 mg at an average dose of 76 IU/day. In the placebo group there was a mean increase of 10.5 IU/day and 18.3 IU/day from baseline (mean average dose of 84 and 92 IU/day) at weeks 48 and 104, respectively. The proportion of subjects remaining in the study at week 104 was 72.4% for the group treated with dapagliflozin 10 mg and 54.8% for the placebo group.</p><p><strong>Table 4. Results of 24-week (LOCF<sup>a</sup>) placebo-controlled studies of dapagliflozin in add-on combination with metformin or sitagliptin (with or without metformin)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td rowspan="2" style="vertical-align:bottom">&nbsp;</td><td colspan="4" style="vertical-align:top"><p><strong>Add-on combination</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metformin</strong><sup>1</sup></p></td><td colspan="2" style="vertical-align:top"><p><strong>DPP-4 inhibitor</strong></p><p><strong>(sitagliptin</strong><sup>2</sup>)<strong>&nbsp;&plusmn; metformin</strong><sup>1</sup></p></td></tr><tr><td style="vertical-align:bottom">&nbsp;</td><td style="vertical-align:top"><p><strong>Dapagliflozin</strong></p><p><strong>10 mg</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td style="vertical-align:top"><p><strong>Dapagliflozin</strong></p><p><strong>10 mg</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>N</strong><sup>b</sup></p></td><td style="vertical-align:top"><p>135</p></td><td style="vertical-align:top"><p>137</p></td><td style="vertical-align:top"><p>223</p></td><td style="vertical-align:top"><p>224</p></td></tr><tr><td style="vertical-align:top"><p><strong>HbA1c (%)</strong></p><p>Baseline (mean)</p><p>Change from baseline<sup>c</sup></p><p>Difference from placebo<sup>c</sup></p><p>(95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>7.92</p><p>-0.84</p><p>-0.54*</p><p>(-0.74, -0.34)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>8.11</p><p>-0.30</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>7.90</p><p>-0.45</p><p>-0.48*</p><p>(-0.62, -0.34)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>7.97</p><p>0.04</p></td></tr><tr><td style="vertical-align:top"><p><strong>Subjects (%) achieving:</strong></p><p><strong>HbA1c &lt; 7%</strong></p><p>Adjusted for baseline</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>40.6**</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>25.9</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Body weight (kg)</strong></p><p>Baseline (mean)</p><p>Change from baseline<sup>c</sup></p><p>Difference from placebo<sup>c</sup></p><p>(95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>86.28</p><p>-2.86</p><p>-1.97*</p><p>(-2.63, -1.31)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>87.74</p><p>-0.89</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>91.02</p><p>-2.14</p><p>-1.89*</p><p>(-2.37, -1.40)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>89.23</p><p>-0.26</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>1</sup>Metformin &ge; 1500 mg/day;</p><p><sup>2</sup>sitagliptin 100 mg/day</p><p><sup>a</sup>LOCF: Last observation (prior to rescue for rescued subjects) carried forward</p><p><sup>b</sup>All randomised subjects who took at least one dose of double-blind study medicinal product during the short-term double-blind period</p><p><sup>c</sup>Least squares mean adjusted for baseline value</p><p>*p-value &lt; 0.0001 versus placebo + oral glucose-lowering medicinal product</p><p>**p-value &lt; 0.05 versus placebo + oral glucose-lowering medicinal product</p></td></tr></tbody></table><p><strong>Table 5. Results of 24-week placebo-controlled studies of dapagliflozin in add-on combination with sulphonylurea (glimepiride) or metformin and a sulphonylurea</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td rowspan="2" style="vertical-align:bottom">&nbsp;</td><td colspan="4" style="vertical-align:top"><p><strong>Add-on combination</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Sulphonylurea</strong></p><p><strong>(glimepiride</strong><sup>1</sup><strong>)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Sulphonylurea + metformin</strong><sup>2</sup></p></td></tr><tr><td style="vertical-align:bottom">&nbsp;</td><td style="vertical-align:top"><p><strong>Dapagliflozin</strong></p><p><strong>10 mg</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td style="vertical-align:top"><p><strong>Dapagliflozin</strong></p><p><strong>10 mg</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>N</strong><sup>a</sup></p></td><td style="vertical-align:top"><p>151</p></td><td style="vertical-align:top"><p>145</p></td><td style="vertical-align:top"><p>108</p></td><td style="vertical-align:top"><p>108</p></td></tr><tr><td style="vertical-align:top"><p><strong>HbA1c (%)</strong><sup>b</sup></p><p>Baseline (mean)</p><p>Change from baseline<sup>c</sup></p><p>Difference from placebo<sup>c</sup></p><p>(95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>8.07</p><p>-0.82</p><p>-0.68*</p><p>(-0.86, -0.51)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>8.15</p><p>-0.13</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>8.08</p><p>-0.86</p><p>&minus;0.69*</p><p>(&minus;0.89, &minus;0.49)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>8.24</p><p>-0.17</p></td></tr><tr><td style="vertical-align:top"><p><strong>Subjects (%) achieving:</strong></p><p><strong>HbA1c &lt; 7% (LOCF)</strong><sup>d</sup></p><p>Adjusted for baseline</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>31.7*</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>13.0</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>31.8*</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>11.1</p></td></tr><tr><td style="vertical-align:top"><p><strong>Body weight (kg) (LOCF)</strong><sup>d</sup></p><p>Baseline (mean)</p><p>Change from baseline<sup>c</sup></p><p>Difference from placebo<sup>c</sup></p><p>(95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>80.56</p><p>-2.26</p><p>-1.54*</p><p>(-2.17, -0.92)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>80.94</p><p>-0.72</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>88.57</p><p>-2.65</p><p>&minus;2.07*</p><p>(&minus;2.79, &minus;1.35)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>90.07</p><p>-0.58</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>1</sup>glimepiride 4 mg/day;&nbsp;<sup>2</sup>Metformin (immediate- or extended-release formulations) &ge;1500 mg/day plus maximum tolerated dose, which must be at least half maximum dose, of a sulphonylurea for at least 8 weeks prior to enrolment.</p><p><sup>a</sup>Randomised and treated patients with baseline and at least 1 post-baseline efficacy measurement.</p><p><sup>b</sup>Columns 1 and 2, HbA1c analysed using LOCF (see footnote d); Columns 3 and 4, HbA1c analysed using LRM (see footnote e)</p><p><sup>c</sup>Least squares mean adjusted for baseline value</p><p><sup>d</sup>LOCF: Last observation (prior to rescue for rescued subjects) carried forward</p><p><sup>e</sup>LRM: Longitudinal repeated measures analysis</p><p>*p-value &lt; 0.0001 versus placebo + oral glucose-lowering medicinal product(s)</p></td></tr></tbody></table><p><strong>Table 6. Results at week 24 (LOCF<sup>a</sup>) in a placebo-controlled study of dapagliflozin in combination with insulin (alone or with oral glucose-lowering medicinal products)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:bottom"><p><strong>Parameter</strong></p></td><td style="vertical-align:top"><p><strong>Dapagliflozin 10 mg</strong></p><p><strong>+ insulin</strong></p><p><strong>&plusmn; oral glucose-lowering medicinal products</strong><sup>2</sup></p></td><td style="vertical-align:bottom"><p><strong>Placebo</strong></p><p><strong>+ insulin</strong></p><p><strong>&plusmn; oral glucose-lowering medicinal products</strong><sup>2</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>N</strong><sup>b</sup></p></td><td style="vertical-align:top"><p>194</p></td><td style="vertical-align:top"><p>193</p></td></tr><tr><td style="vertical-align:top"><p><strong>HbA1c (%)</strong></p><p>Baseline (mean)</p><p>Change from baseline<sup>c</sup></p><p>Difference from placebo<sup>c</sup></p><p>(95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>8.58</p><p>-0.90</p><p>-0.60*</p><p>(-0.74, -0.45)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>8.46</p><p>-0.30</p></td></tr><tr><td style="vertical-align:top"><p><strong>Body weight (kg)</strong></p><p>Baseline (mean)</p><p>Change from baseline<sup>c</sup></p><p>Difference from placebo<sup>c</sup></p><p>(95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>94.63</p><p>-1.67</p><p>-1.68*</p><p>(-2.19, -1.18)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>94.21</p><p>0.02</p></td></tr><tr><td style="vertical-align:top"><p><strong>Mean daily insulin dose (IU)</strong><sup>1</sup></p><p>Baseline (mean)</p><p>Change from baseline<sup>c</sup></p><p>Difference from placebo<sup>c</sup></p><p>(95% CI)</p><p>Subjects with mean daily insulin dose reduction of at least 10% (%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>77.96</p><p>-1.16</p><p>-6.23*</p><p>(-8.84, -3.63)</p><p>19.7**</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>73.96</p><p>5.08</p><p>&nbsp;</p><p>&nbsp;</p><p>11.0</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup>LOCF: Last observation (prior to or on the date of the first insulin up-titration, if needed) carried forward</p><p><sup>b</sup>All randomised subjects who took at least one dose of double-blind study medicinal product during the short-term double-blind period</p><p><sup>c</sup>Least squares mean adjusted for baseline value and presence of oral glucose-lowering medicinal product</p><p>*p-value &lt; 0.0001 versus placebo + insulin &plusmn; oral glucose-lowering medicinal product</p><p>**p-value &lt; 0.05 versus placebo + insulin &plusmn; oral glucose-lowering medicinal product</p><p><sup>1</sup>Up-titration of insulin regimens (including short-acting, intermediate, and basal insulin) was only allowed if subjects met pre-defined FPG criteria.</p><p><sup>2</sup>Fifty percent of subjects were on insulin monotherapy at baseline; 50% were on 1 or 2 oral glucose-lowering medicinal product(s) in addition to insulin: Of this latter group, 80% were on metformin alone, 12% were on metformin plus sulphonylurea therapy, and the rest were on other oral glucose-lowering medicinal products.</p></td></tr></tbody></table><p><em>In combination with metformin in drug-naive patients</em></p><p>A total of 1,236 drug-naive patients with inadequately controlled type 2 diabetes (HbA1c &ge; 7.5% and &le; 12%) participated in two active-controlled studies of 24 weeks duration to evaluate the efficacy and safety of dapagliflozin (5 mg or 10 mg) in combination with metformin in drug-naive patients versus therapy with the monocomponents.</p><p>Treatment with dapagliflozin 10 mg in combination with metformin (up to 2000 mg per day) provided significant improvements in HbA1c compared to the individual components (Table 7), and led to greater reductions in fasting plasma glucose (FPG) (compared to the individual components) and body weight (compared to metformin).</p><p><strong>Table 7. Results at week 24 (LOCF<sup>a</sup>) in an active-controlled study of dapagliflozin and metformin combination therapy in drug-naive patients</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:bottom"><p><strong>Parameter</strong></p></td><td style="vertical-align:top"><p><strong>Dapagliflozin 10 mg + metformin</strong></p></td><td style="vertical-align:top"><p><strong>Dapagliflozin 10 mg</strong></p></td><td style="vertical-align:top"><p><strong>Metformin</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>N</strong><sup>b</sup></p></td><td style="vertical-align:top"><p>211<sup>b</sup></p></td><td style="vertical-align:top"><p>219<sup>b</sup></p></td><td style="vertical-align:top"><p>208<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>HbA1c (%)</strong></p><p>Baseline (mean)</p><p>Change from baseline<sup>c</sup></p><p>Difference from dapagliflozin<sup>c</sup></p><p>(95% CI)</p><p>Difference from metformin<sup>c</sup></p><p>(95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>9.10</p><p>-1.98</p><p>&minus;0.53*</p><p>(&minus;0.74, &minus;0.32)</p><p>&minus;0.54*</p><p>(&minus;0.75, &minus;0.33)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>9.03</p><p>-1.45</p><p>&nbsp;</p><p>&nbsp;</p><p>&minus;0.01</p><p>(&minus;0.22, 0.20)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>9.03</p><p>-1.44</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><sup>a</sup>LOCF: last observation (prior to rescue for rescued patients) carried forward.</p><p><sup>b</sup>All randomised patients who took at least one dose of double-blind study medicinal product during the short-term double-blind period.</p><p><sup>c</sup>Least squares mean adjusted for baseline value.</p><p>*p-value &lt;0.0001.</p></td></tr></tbody></table><p><em>Combination therapy with prolonged-release exenatide</em></p><p>In a 28-week, double-blind, active comparator-controlled study, the combination of dapagliflozin and prolonged-release exenatide (a GLP-1 receptor agonist) was compared to dapagliflozin alone and prolonged-release exenatide alone in subjects with inadequate glycaemic control on metformin alone (HbA1c &ge; 8% and &le; 12%). All treatment groups had a reduction in HbA1c compared to baseline. The combination treatment with dapagliflozin 10 mg and prolonged-release exenatide group showed superior reductions in HbA1c from baseline compared to dapagliflozin alone and prolonged-release exenatide alone (Table 8).</p><p><strong>Table 8. Results of one 28-week study of dapagliflozin and prolonged-release exenatide versus dapagliflozin alone and prolonged-release exenatide alone, in combination with metformin (intent to treat patients)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:bottom"><p><strong>Parameter</strong></p></td><td style="vertical-align:top"><p><strong>Dapagliflozin 10 mg QD</strong></p><p><strong>+</strong></p><p><strong>prolonged-release exenatide 2 mg QW</strong></p></td><td style="vertical-align:top"><p><strong>Dapagliflozin 10 mg QD</strong></p><p><strong>+</strong></p><p><strong>placebo QW</strong></p></td><td style="vertical-align:top"><p><strong>Prolonged-release exenatide 2 mg QW</strong></p><p><strong>+</strong></p><p><strong>placebo QD</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>N</strong></p></td><td><p><strong>228</strong></p></td><td><p><strong>230</strong></p></td><td><p><strong>227</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>HbA1c (%)</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td><p>9.29</p></td><td><p>9.25</p></td><td><p>9.26</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline<sup>a</sup></p></td><td><p>-1.98</p></td><td><p>-1.39</p></td><td><p>-1.60</p></td></tr><tr><td><p>Mean difference in change from baseline between combination and single medicinal product (95% CI)</p></td><td style="vertical-align:top">&nbsp;</td><td><p>-0.59*</p><p>(-0.84, -0.34)</p></td><td><p>-0.38**</p><p>(-0.63, -0.13)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Subjects (%) achieving HbA1c&nbsp;</strong>&lt;&nbsp;<strong>7%</strong></p></td><td><p>44.7</p></td><td><p>19.1</p></td><td><p>26.9</p></td></tr><tr><td style="vertical-align:top"><p><strong>Body weight (kg)</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td><p>92.13</p></td><td><p>90.87</p></td><td><p>89.12</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline<sup>&nbsp;a</sup></p></td><td><p>-3.55</p></td><td><p>-2.22</p></td><td><p>-1.56</p></td></tr><tr><td><p>Mean difference in change from baseline between combination and single medicinal product (95% CI)</p></td><td style="vertical-align:top">&nbsp;</td><td><p>-1.33*</p><p>(-2.12, -0.55)</p></td><td><p>-2.00*</p><p>(-2.79, -1.20)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>QD=once daily, QW=once weekly, N=number of patients, CI=confidence interval.</p><p><sup>a</sup>Adjusted least squares means (LS Means) and treatment group difference(s) in the change from baseline values at week 28 are modelled using a mixed model with repeated measures (MMRM) including treatment, region, baseline HbA1c stratum (&lt; 9.0% or &ge; 9.0%), week, and treatment by week interaction as fixed factors, and baseline value as a covariate.</p><p>*p &lt; 0.001, **p &lt; 0.01.</p><p>P-values are all adjusted p-values for multiplicity.</p><p>Analyses exclude measurements post rescue therapy and post premature discontinuation of study medicinal product.</p></td></tr></tbody></table><p><em><u>Fasting plasma glucose</u></em></p><p>Treatment with dapagliflozin 10 mg as a monotherapy or as an add-on to either metformin, glimepiride, metformin and a sulphonylurea, sitagliptin (with or without metformin) or insulin resulted in statistically significant reductions in FPG (-1.90 to -1.20 mmol/L [-34.2 to -21.7 mg/dL]) compared to placebo (-0.33 to 0.21 mmol/L [-6.0 to 3.8 mg/dL]). This effect was observed at week 1 of treatment and maintained in studies extended through week 104.</p><p>Combination therapy of dapagliflozin 10 mg and prolonged-release exenatide resulted in significantly greater reductions in FPG at week 28: -3.66 mmol/L (-65.8 mg/dL), compared to -2.73 mmol/L (-49.2 mg/dL) for dapagliflozin alone (p &lt; 0.001) and -2.54 mmol/L (-45.8 mg/dL) for exenatide alone (p &lt; 0.001).</p><p>In a dedicated study in diabetic patients with an eGFR &ge; 45 to &lt; 60 mL/min/1.73 m<sup>2</sup>, treatment with dapagliflozin demonstrated reductions in FPG at week 24: -1.19 mmol/L (-21.46 mg/dL) compared to -0.27 mmol/L (-4.87 mg/dL) for placebo (p=0.001).</p><p><em><u>Post-prandial glucose</u></em></p><p>Treatment with dapagliflozin 10 mg as an add-on to glimepiride resulted in statistically significant reductions in 2-hour post-prandial glucose at 24 weeks that were maintained up to week 48.</p><p>Treatment with dapagliflozin 10 mg as an add-on to sitagliptin (with or without metformin) resulted in reductions in 2-hour post-prandial glucose at 24 weeks that were maintained up to week 48.</p><p>Combination therapy of dapagliflozin 10 mg and prolonged-release exenatide resulted in significantly greater reductions in 2-hour post-prandial glucose at week 28 compared to either medicinal product alone.</p><p><em><u>Body weight</u></em></p><p>Dapagliflozin 10 mg as an add-on to metformin, glimepiride, metformin and a sulphonylurea, sitagliptin (with or without metformin) or insulin resulted in statistically significant body weight reduction at 24 weeks (p &lt; 0.0001, Tables 4 and 5). These effects were sustained in longer-term studies. At 48 weeks, the difference for dapagliflozin as add-on to sitagliptin (with or without metformin) compared with placebo was -2.22 kg. At 102 weeks, the difference for dapagliflozin as add-on to metformin compared with placebo, or as add-on to insulin compared with placebo was -2.14 and -2.88 kg, respectively.</p><p>As an add-on therapy to metformin in an active-controlled non-inferiority study, dapagliflozin resulted in a statistically significant body weight reduction compared with glipizide of -4.65 kg at 52 weeks (p &lt; 0.0001, Table 3) that was sustained at 104 and 208 weeks (-5.06 kg and &ndash;4.38 kg, respectively).</p><p>The combination of dapagliflozin 10 mg and prolonged-release exenatide demonstrated significantly greater weight reductions compared to either medicinal product alone (Table 8).</p><p>A 24-week study in 182 diabetic subjects using dual energy X-ray absorptiometry (DXA) to evaluate body composition demonstrated reductions with dapagliflozin 10 mg plus metformin compared with placebo plus metformin, respectively, in body weight and body fat mass as measured by DXA rather than lean tissue or fluid loss. Treatment with dapagliflozin plus metformin showed a numerical decrease in visceral adipose tissue compared with placebo plus metformin treatment in a magnetic resonance imaging substudy.</p><p><em><u>Blood pressure</u></em></p><p>In a pre-specified pooled analysis of 13 placebo-controlled studies, treatment with dapagliflozin 10 mg resulted in a systolic blood pressure change from baseline of &ndash;3.7 mmHg and diastolic blood pressure of &ndash;1.8 mmHg versus &ndash;0.5 mmHg systolic and -0.5 mmHg diastolic blood pressure for placebo group at week 24. Similar reductions were observed up to 104 weeks.</p><p>Combination therapy of dapagliflozin 10 mg and prolonged-release exenatide resulted in a significantly greater reduction in systolic blood pressure at week 28 (-4.3 mmHg) compared to dapagliflozin alone (-1.8 mmHg, p &lt; 0.05) and prolonged-release exenatide alone (-1.2 mmHg, p &lt; 0.01).</p><p>In two 12-week, placebo-controlled studies a total of 1,062 patients with inadequately controlled type 2 diabetes and hypertension (despite pre-existing stable treatment with an ACE-I or ARB in one study and an ACE-I or ARB plus one additional antihypertensive treatment in another study) were treated with dapagliflozin 10 mg or placebo. At week 12 for both studies, dapagliflozin 10 mg plus usual antidiabetic treatment provided improvement in HbA1c and decreased the placebo-corrected systolic blood pressure on average by 3.1 and 4.3 mmHg, respectively.</p><p>In a dedicated study in diabetic patients with an eGFR &ge; 45 to &lt; 60 mL/min/1.73 m<sup>2</sup>, treatment with dapagliflozin demonstrated reductions in seated systolic blood pressure at week 24: -4.8 mmHg compared to -1.7 mmHg for placebo (p &lt; 0.05).</p><p><em><u>Glycaemic control in patients with moderate renal impairment CKD 3A (eGFR &ge; 45 to &lt; 60 mL/min/1.73 m<sup>2</sup>)</u></em></p><p>The efficacy of dapagliflozin was assessed in a dedicated study in diabetic patients with an eGFR &ge; 45 to &lt; 60 mL/min/1.73 m<sup>2</sup>&nbsp;who had inadequate glycaemic control on usual care. Treatment with dapagliflozin resulted in reductions in HbA1c and body weight compared with placebo (Table 9).</p><p><strong>Table 9. Results at week 24 of a placebo-controlled study of dapagliflozin in diabetic patients with an eGFR &ge; 45 to &lt; 60 mL/min/1.73 m<sup>2</sup></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:bottom">&nbsp;</td><td style="vertical-align:top"><p><strong>Dapagliflozin</strong><sup>a</sup></p><p><strong>10 mg</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong><sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>N<sup>b</sup></strong></p></td><td style="vertical-align:top"><p><strong>159</strong></p></td><td style="vertical-align:top"><p><strong>161</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>HbA1c (%)</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>8.35</p></td><td style="vertical-align:top"><p>8.03</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline<sup>b</sup></p></td><td style="vertical-align:top"><p>-0.37</p></td><td style="vertical-align:top"><p>-0.03</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo<sup>b</sup></p><p>(95% CI)</p></td><td style="vertical-align:top"><p>-0.34*</p><p>(-0.53, -0.15)</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Body weight (kg)</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>92.51</p></td><td style="vertical-align:top"><p>88.30</p></td></tr><tr><td style="vertical-align:top"><p>Percent change from baseline<sup>c</sup></p></td><td style="vertical-align:top"><p>-3.42</p></td><td style="vertical-align:top"><p>-2.02</p></td></tr><tr><td style="vertical-align:top"><p>Difference in percent change from placebo<sup>c</sup></p><p>(95% CI)</p></td><td style="vertical-align:top"><p>-1.43*</p><p>(-2.15, -0.69)</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup>&nbsp;Metformin or metformin hydrochloride were part of the usual care in 69.4% and 64.0% of the patients for the dapagliflozin and placebo groups, respectively.</p><p><sup>b</sup>&nbsp;Least squares mean adjusted for baseline value</p><p><sup>c&nbsp;</sup>Derived from least squares mean adjusted for baseline value</p><p>* p&lt;0.001</p></td></tr></tbody></table><p><em><u>Patients with baseline HbA1c &ge; 9%</u></em></p><p>In a pre-specified analysis of subjects with baseline HbA1c &ge; 9.0%, treatment with dapagliflozin 10 mg resulted in statistically significant reductions in HbA1c at week 24 as a monotherapy (adjusted mean change from baseline: -2.04% and 0.19% for dapagliflozin 10 mg and placebo, respectively) and as an add-on to metformin (adjusted mean change from baseline: -1.32% and -0.53% for dapagliflozin and placebo, respectively).</p><p><em><u>Cardiovascular and renal outcomes</u></em></p><p>Dapagliflozin Effect on Cardiovascular Events (DECLARE) was an international, multicentre, randomised, double-blind, placebo-controlled clinical study conducted to determine the effect of dapagliflozin compared with placebo on cardiovascular outcomes when added to current background therapy. All patients had type 2 diabetes mellitus and either at least two additional cardiovascular risk factors (age &ge; 55 years in men or &ge; 60 years in women and one or more of dyslipidaemia, hypertension or current tobacco use) or established cardiovascular disease.</p><p>Of 17,160 randomised patients, 6,974 (40.6%) had established cardiovascular disease and 10,186 (59.4%) did not have established cardiovascular disease. 8,582 patients were randomised to dapagliflozin 10 mg and 8,578 to placebo, and were followed for a median of 4.2 years.</p><p>The mean age of the study population was 63.9 years, 37.4% were female. In total, 22.4% had had diabetes for &le; 5 years, mean duration of diabetes was 11.9 years. Mean HbA1c was 8.3% and mean BMI was 32.1 kg/m<sup>2</sup>.</p><p>Most patients (98%) used one or more diabetic medicinal products at baseline, including metformin (82%), insulin (41%) and sulfonylurea (43%).</p><p><em>Major adverse cardiovascular events</em></p><p>Dapagliflozin 10 mg demonstrated non-inferiority versus placebo for the composite of cardiovascular death, myocardial infarction or ischaemic stroke (one-sided p &lt; 0.001).</p><p><em>Nephropathy</em></p><p>Dapagliflozin reduced the incidence of events of the composite of confirmed sustained eGFR decrease, end-stage kidney disease, renal or cardiovascular death. The difference between groups was driven by reductions in events of the renal components; sustained eGFR decrease, end-stage kidney disease and renal death.</p><p>The hazard ratio (HR) for time to nephropathy (sustained eGFR decrease, end-stage kidney disease and renal death) was 0.53 (95% CI 0.43, 0.66) for dapagliflozin versus placebo.</p><p>In addition, dapagliflozin reduced the new onset of sustained albuminuria (HR 0.79 [95% CI 0.72, 0.87]) and led to greater regression of macroalbuminuria (HR 1.82 [95% CI 1.51, 2.20]) compared with placebo.</p><p><em><u>Nephropathy</u></em></p><p>There were few events of the renal composite endpoint (confirmed sustained &ge; 50% eGFR decrease, ESKD, or renal death); the incidence was 1.2% in the dapagliflozin group and 1.6% in the placebo group.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Dapagliflozin was rapidly and well absorbed after oral administration. Maximum dapagliflozin plasma concentrations (C<sub>max</sub>) were usually attained within 2 hours after administration in the fasted state. Geometric mean steady-state dapagliflozin C<sub>max</sub>&nbsp;and AUC&nbsp;values following once daily 10 mg doses of dapagliflozin were 158 ng/mL and 628 ng h/mL, respectively. The absolute oral bioavailability of dapagliflozin following the administration of a 10 mg dose is 78%. Administration with a high-fat meal decreased dapagliflozin C<sub>max</sub>&nbsp;by up to 50% and prolonged T<sub>max</sub>&nbsp;by approximately 1 hour, but did not alter AUC as compared with the fasted state. These changes are not considered to be clinically meaningful. Hence, dapagliflozin can be administered with or without food.</p><p><u>Distribution</u></p><p>Dapagliflozin is approximately 91% protein bound. Protein binding was not altered in various disease states (e.g. renal or hepatic impairment). The mean steady-state volume of distribution of dapagliflozin was 118 liters.</p><p><u>Biotransformation</u></p><p>Dapagliflozin is extensively metabolised, primarily to yield dapagliflozin 3-O-glucuronide, which is an inactive metabolite. Dapagliflozin 3-O-glucuronide or other metabolites do not contribute to the glucose-lowering effects. The formation of dapagliflozin 3-O-glucuronide is mediated by UGT1A9, an enzyme present in the liver and kidney, and CYP-mediated metabolism was a minor clearance pathway in humans.</p><p><u>Elimination</u></p><p>The mean plasma terminal half-life (t<sub>1/2</sub>) for dapagliflozin was 12.9 hours following a single oral dose of dapagliflozin 10 mg to healthy subjects. The mean total systemic clearance of dapagliflozin administered intravenously was 207 mL/min. Dapagliflozin and related metabolites are primarily eliminated via urinary excretion with less than 2% as unchanged dapagliflozin. After administration of a 50 mg [<sup>14</sup>C]-dapagliflozin dose, 96% was recovered, 75% in urine and 21% in faeces. In faeces, approximately 15% of the dose was excreted as parent drug.</p><p><u>Linearity</u></p><p>Dapagliflozin exposure increased proportional to the increment in dapagliflozin dose over the range of 0.1 to 500 mg and its pharmacokinetics did not change with time upon repeated daily dosing for up to 24 weeks.</p><p><u>Special populations</u></p><p><em><u>Renal impairment</u></em></p><p>At steady-state (20 mg once-daily dapagliflozin for 7 days), subjects with type 2 diabetes mellitus and mild, moderate or severe renal impairment (as determined by iohexol plasma clearance) had mean systemic exposures of dapagliflozin of 32%, 60% and 87% higher, respectively, than those of subjects with type 2 diabetes mellitus and normal renal function. The steady-state 24-hour urinary glucose excretion was highly dependent on renal function and 85, 52, 18 and 11 g of glucose/day was excreted by subjects with type 2 diabetes mellitus and normal renal function or mild, moderate or severe renal impairment, respectively. The impact of haemodialysis on dapagliflozin exposure is not known. The effect of reduced renal function on systemic exposure was evaluated in a population pharmacokinetic model.</p><p><em><u>Hepatic impairment</u></em></p><p>In subjects with mild or moderate hepatic impairment (Child-Pugh classes A and B), mean C<sub>max</sub>&nbsp;and AUC of dapagliflozin were up to 12% and 36% higher, respectively, compared to healthy matched control subjects. These differences were not considered to be clinically meaningful. In subjects with severe hepatic impairment (Child-Pugh class C) mean C<sub>max</sub>&nbsp;and AUC of dapagliflozin were 40% and 67% higher than matched healthy controls, respectively.</p><p><em><u>Elderly (&ge; 65 years)</u></em></p><p>There is no clinically meaningful increase in exposure based on age alone in subjects up to 70 years old. However, an increased exposure due to age-related decrease in renal function can be expected. There are insufficient data to draw conclusions regarding exposure in patients &gt; 70 years old.</p><p><em><u>Paediatric population</u></em></p><p>Pharmacokinetics in the paediatric population have not been studied.</p><p><em><u>Gender</u></em></p><p>The mean dapagliflozin AUC<sub>ss</sub>&nbsp;in females was estimated to be about 22% higher than in males.</p><p><em><u>Race</u></em></p><p>There were no clinically relevant differences in systemic exposures between White, Black or Asian races.</p><p><em><u>Body weight</u></em></p><p>Dapagliflozin exposure was found to decrease with increased weight. Consequently, low-weight patients may have somewhat increased exposure and patients with high weight somewhat decreased exposure. However, the differences in exposure were not considered clinically meaningful.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential and fertility. Dapagliflozin did not induce tumours in either mice or rats at any of the doses evaluated in two-year carcinogenicity studies.</p><p><u>Reproductive and developmental toxicity</u></p><p>Direct administration of dapagliflozin to weanling juvenile rats and indirect exposure during late pregnancy (time periods corresponding to the second and third trimesters of pregnancy with respect to human renal maturation) and lactation are each associated with increased incidence and/or severity of renal pelvic and tubular dilatations in progeny.</p><p>In a juvenile toxicity study, when dapagliflozin was dosed directly to young rats from postnatal day 21 until postnatal day 90, renal pelvic and tubular dilatations were reported at all dose levels; pup exposures at the lowest dose tested were &ge; 15 times the maximum recommended human dose. These findings were associated with dose-related increases in kidney weight and macroscopic kidney enlargement observed at all doses. The renal pelvic and tubular dilatations observed in juvenile animals did not fully reverse within the approximate 1-month recovery period.</p><p>In a separate study of pre- and postnatal development, maternal rats were dosed from gestation day 6 through postnatal day 21, and pups were indirectly exposed&nbsp;<em>in utero</em>&nbsp;and throughout lactation. (A satellite study was conducted to assess dapagliflozin exposures in milk and pups.) Increased incidence or severity of renal pelvic dilatation was observed in adult offspring of treated dams, although only at the highest dose tested (associated maternal and pup dapagliflozin exposures were 1,415 times and 137 times, respectively, the human values at the maximum recommended human dose). Additional developmental toxicity was limited to dose-related reductions in pup body weights, and observed only at doses &ge; 15 mg/kg/day (associated with pup exposures that are &ge; 29 times the human values at the maximum recommended human dose). Maternal toxicity was evident only at the highest dose tested, and limited to transient reductions in body weight and food consumption at dose. The no observed adverse effect level (NOAEL) for developmental toxicity, the lowest dose tested, is associated with a maternal systemic exposure multiple that is approximately 19 times the human value at the maximum recommended human dose.</p><p>In additional studies of embryo-foetal development in rats and rabbits, dapagliflozin was administered for intervals coinciding with the major periods of organogenesis in each species. Neither maternal nor developmental toxicities were observed in rabbits at any dose tested; the highest dose tested is associated with a systemic exposure multiple of approximately 1,191 times the maximum recommended human dose. In rats, dapagliflozin was neither embryolethal nor teratogenic at exposures up to 1,441 times the maximum recommended human dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose Anhydrous, microcrystalline cellulose, crospovidone, colloidal anhydrous silica, magnesium stearate, Opadry II Yellow Powder (Polyvinyl alcohol, titanium dioxide, Macrogol/ PEG, talc, yellow iron oxide).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Dezeroga<sup>&reg;</sup> 10 mg:</strong> Yellow diamond biconvex beveled edge film coated tablet engraved with C37 on one face and plain on the other face, presented in Alu/Alu blisters, intended for oral use.</p><p><strong>Pack Size:</strong></p><p>28 Film Coated Tablets</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Med City Pharma-KSA.
1st Industrial city, Phase 5, Jeddah –KSA.
Tel: 0096698003288
Mobile: 00966555786968
P.O .Box: 4072 - Jeddah 22429
E-mail: info@medcitypharma.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                07/2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>